Stage II, III or IV disease as defined by the Ann Arbor Staging SystemXx_NEWLINE_xXPatients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites; the following disease groups are eligible:\r\n* Patients with International Neuroblastoma Risk Group (INRG) stage M disease are eligible if found to have either of the following features: \r\n** MYCN amplification (> 4-fold increase in MYCN signals as compared to reference signals), regardless of age or additional biologic features; OR \r\n** Age > 547 days regardless of biologic features\r\n* Patients with INRG stage MS disease with MYCN amplification\r\n* Patients with INRG stage L2 disease with MYCN amplification \r\n* Patients > 547 days of age initially diagnosed with INRG stage L1, L2 or MS disease who progressed to Stage M without prior chemotherapy may enroll within 4 weeks of progression to Stage M\r\n* Patients >= 365 days of age initially diagnosed with MYCN amplified INRG stage L1 disease who progress to Stage M without systemic therapy may enroll within 4 weeks of progression to stage MXx_NEWLINE_xXClinical stage II (T3-4, N-) or stage III (any T, N+) based on magnetic resonance imaging (MRI)Xx_NEWLINE_xXNYHA classification of III or IVXx_NEWLINE_xXPatients must have undergone complete surgical resection of their stage IB (>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowedXx_NEWLINE_xXClinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th editionXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV or unresectable stage III BRAF V600E or BRAF V600K mutant melanomaXx_NEWLINE_xXPatients must have unresectable stage III or stage IV diseaseXx_NEWLINE_xXPatients must have histologically or cytologically confirmed extensive stage small cell lung cancer and must be a candidate for systemic therapy; NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathyXx_NEWLINE_xXPatients who have received prior chemoradiation for limited-stage SCLC must have been treated with curative intent at least 6 months since last treatment from diagnosis of extensive-stage SCLCXx_NEWLINE_xXPatients must have pathologically confirmed melanoma that is either stage IV or unresectable stage III; patients may have primaries of cutaneous, mucosal or unknown origin; patients with uveal (ocular) primary are not eligibleXx_NEWLINE_xXStage IV disease (includes M1a, M1b, or recurrent disease), according to the 7th edition of the lung cancer tumor, node, and metastasis (TNM) classification systemXx_NEWLINE_xXLow risk stratum (stage I ovarian immature teratoma and stage I malignant GCT [all sites]): Patients must be < 50 years of age at enrollmentXx_NEWLINE_xXLow risk stage I immature teratoma (IT); site: ovarian; stage: Children's Oncology Group (COG) stage I, Federation of Gynecology and Obstetrics (FIGO) stage IA and IB; grade: 2 or 3; histology: pure immature teratoma, mixed immature and mature teratoma, (no pathological evidence of mediastinal germ cell tumor [MGCT]); tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; age (years) < 50Xx_NEWLINE_xXLow risk stage I MCGT; site: ovarian, testicular, or extragonadal; stage: COG stage I, FIGO stage IA and IB, American Joint Committee on Cancer (AJCC) testicular stage IA and IB; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); age (years) < 50Xx_NEWLINE_xXStandard risk 1 (SR1); site: ovarian, testicular, or extragonadal; stage: COG stage II-IV, FIGO stage IC, FIGO stage II-IV; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); age (years) < 11Xx_NEWLINE_xXStandard risk 2 (SR2)\r\n* Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); age (years) >= 11 and < 25\r\n* Site: testicular; stage: COG stage II-IV, AJCC stage II, III, International Germ Cell Consensus Classification (IGCCC) good risk; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed); tumor markers: for IGCCC good risk: alpha-FP < 1,000 ng/mL, beta-HCG < 5,000 IU/mL and lactate dehydrogenase (LDH) < 1.5 x normal; age (years) >= 11 and < 25\r\n* Site: extragonadal; stage: COG stage II; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma (pure or mixed) age (years) >= 11 and < 25Xx_NEWLINE_xXPatients with any diagnoses not listed including:\r\n* Stage I testicular cancer patients who have undergone primary RPLND (retroperitoneal lymph node dissection)\r\n* Pure dysgerminoma and pure seminoma\r\n* Pure mature teratoma\r\n* Pure immature teratoma COG stage I with alpha-fetoprotein (AFP) >= 1000 ng/mL\r\n* Pure immature teratoma COG stage II - IV or FIGO stage IC to IV\r\n* Poor risk disease (age >= 11 years old and COG stage IV ovarian, COG stage III or IV EG, or IGCCC intermediate or poor risk testicular), or\r\n* Primary central nervous system (CNS) germ cell tumorXx_NEWLINE_xXStage T2a/b (> 5 cm) and grade 2 or 3 ANDXx_NEWLINE_xXRMS types included under embryonal rhabdomyosarcoma (ERMS) include those classified in the 1995 International Classification of Rhabdomyosarcoma (ICR) as ERMS (classic, spindle cell, and botryoid variants), which are reclassified in the 2013 World Health Organization (WHO) classification as ERMS (classic, dense and botryoid variants) and spindle cell/sclerosing RMS (encompassing the historical spindle cell ERMS variant and the newly recognized sclerosing RMS variant); classification of alveolar rhabdomyosarcoma (ARMS) in the 2013 WHO classification is the same as in the ICR and includes classic and solid variants\r\n* ERMS\r\n** Stage 1, group III (non-orbit)\r\n** Stage 3, group I/II\r\n** Stage 2/3, group III\r\n** Stage 4, group IV, < 10 years old\r\n* ARMS:\r\n** Stages 1-3, groups I-IIIXx_NEWLINE_xXParticipants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition staging criteriaXx_NEWLINE_xXPatients must have either metastatic (stage IVC) or locally advanced unresectable disease (stage IVB)Xx_NEWLINE_xXPatients must be:\r\n* < 12 months (< 365 days) of age at diagnosis with INRG stage L1; or\r\n* < 18 months (< 547 days) of age at diagnosis with INRG stage L2 or stage Ms neuroblastoma/ganglioneuroblastomaXx_NEWLINE_xXPatients with newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages are eligible:\r\n* Stage IIB with bulk\r\n* Stage IIIB\r\n* Stage IVA\r\n* Stage IVB\r\n** If study eligibility by staging is uncertain, consultation with Imaging and Radiation Oncology Core (IROC) Rhode Island (RI) may be obtained prior to study enrollmentXx_NEWLINE_xXPathologically proven diagnosis of NSCLC, with metastases (stage IV disease) present prior to registration; this includes patients newly diagnosed with metastatic disease or those initially diagnosed and treated for stage I-III NSCLC who ultimately develop metastases.Xx_NEWLINE_xXPatients must have stage II, III, or IV diseaseXx_NEWLINE_xXPatients with stage I disease are not eligibleXx_NEWLINE_xXPatients must have histologically proven, recurrent, non-muscle invasive urothelial carcinoma of the bladder within 60 days prior to registration; the carcinoma must be stage T1 high-grade, stage CIS, or stage Ta high-gradeXx_NEWLINE_xXPatients with apparent stage I disease who have not undergone a staging procedureXx_NEWLINE_xXPre- and postmenopausal women or men with Stage II (Stage IIA limited to max. 1000 patients) or Stage III early invasive breast cancerXx_NEWLINE_xXPatients with Stage I or IV breast cancer are not eligible.Xx_NEWLINE_xXLimited-stage patients who are candidates for local or regional therapyXx_NEWLINE_xXSubjects who are 12-18 months of age with INSS Stage 4 and all stage 3 subjects with favorable biologic features (ie, nonamplified MYCN, favorable pathology, and DNA index > 1) are not eligible.Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of non-small cell lung carcinoma (NSCLC) who present with stage IIIB/stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resectionXx_NEWLINE_xXPatients with unresectable or metastatic stage III B/C or IV melanoma. Patients enrolled under this version of the protocol must also have progressed on prior anti-PD-1 therapy, according to RECIST 1.1 criteria. Patients who progressed within 3 months of treatment start are excluded.Xx_NEWLINE_xXPatients must have histologically confirmed diagnosis of stage IV metastatic melanoma positive for BRAF V600E by a Clinical Laboratory Improvement Amendments (CLIA) approved assayXx_NEWLINE_xXStage III-IV SCCHN and select stage II participants (T2N0 oral cavity cancer with > 5 mm depth invasion)Xx_NEWLINE_xXAny patient with inflammatory breast cancer or stage IV or confirmed metastatic diseaseXx_NEWLINE_xXSubjects must have histologically confirmed metastatic melanoma with measurable (by RECIST v1.1), stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease that is accessible for injection.Xx_NEWLINE_xXPatients must have histologically confirmed invasive breast cancer with stage IV disease, either biopsy proven or with unequivocal evidence of metastatic disease by physical examination or radiological studyXx_NEWLINE_xXCuratively treated Stage I uterine cancerXx_NEWLINE_xXClinical Diagnosis of CTCL stage IA, IB, or IIA with biopsy within last 3 monthsXx_NEWLINE_xXCTCL that is stage IIB or great or stage IIA with stage N2 with >5% circulating Sezary cells or CD8+ or large cell transformation or Progressive CTCLXx_NEWLINE_xXMust have unresectable or inoperable stage IIIA or IIIB disease; subjects must be considered unresectable or inoperable based on the judgment of the treating physicianXx_NEWLINE_xXHistologically or cytologically proven advanced (stage IIIB/IV) NSCLC subjects who are immunotherapy naïve.Xx_NEWLINE_xXHistologically-confirmed stage IIIb or IV NSCLC by the enrolling institution\r\n* Patients who are highly suspected to have stage IIIb or IV NSCLC and who are planned for a standard-of-care diagnostic biopsy/resection may also be enrolled; patients who are confirmed to have stage IIIb or IV NSCLC will be eligible to continue with screening procedures; those who are found after surgery/biopsy to not have stage IIIb or IV NSCLC will not be eligible continue with screening procedures and may not receive study therapyXx_NEWLINE_xXHistologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) staging systemXx_NEWLINE_xXPhase 1: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (American Joint Committee on Cancer [AJCC] stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by fluorescence in situ hybridization (FISH), reverse transcription polymerase chain reaction (RT-PCR), or next generation sequencing (NGS) via a Clinical Laboratory Improvement Act (CLIA)-certified local diagnostic test (LDT); ORXx_NEWLINE_xXPhase 2 Cohorts A & B: Subjects must have a histologically or cytologically confirmed diagnosis of locally advanced (AJCC stage IIIB) not amenable to curative therapy or metastatic (AJCC stage IV) NSCLC that carries a RET rearrangement, as determined by FISH, RT-PCR, or NGS via a CLIA-certified LDTXx_NEWLINE_xXAnn Arbor stage II-IV disease (Stage I primary mediastinal B-cell lymphoma will also be eligible)Xx_NEWLINE_xXStage B (not applicable for transarterial chemoembolization [TACE]), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging systemXx_NEWLINE_xXPatients must have histologically or cytologically confirmed squamous cell carcinoma (SCC) of the oral cavity, oropharynx, hypopharynx or larynx; patients eligible for inclusion must have stage III-IV SCC of the above sites based on current American Joint Committee on Cancer (AJCC) clinical and imaging based staging; only patients with human papillomavirus (HPV)- disease will be included in the phase II portion of the study; HPV status will be ascertained using the currently utilized clinical standard of p16 overexpression via immunohistochemistryXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Disease stage IV, metastatic unresectable diseaseXx_NEWLINE_xXHistologically confirmed newly diagnosed stage I-II HER2/neu positive breast cancerXx_NEWLINE_xXStage IV or metastatic breast cancerXx_NEWLINE_xXStage IV melanoma for which surgery is not recommended.Xx_NEWLINE_xXPatients with confirmed stage IV diseaseXx_NEWLINE_xXCytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009).Xx_NEWLINE_xXMandatory provision of adequate archived stage IV NSCLC tissue samples or tissue samples other than stage IV NSCLC may be acceptable (optional for part C).Xx_NEWLINE_xXUnresected operable breast cancer stage II-III with primary tumor > 2.0 cmXx_NEWLINE_xXParticipants must have histologically or cytologically confirmed stage IV melanoma or recurrent stage IIIc melanoma following primary treatment of surgery and prior treatment or consideration of adjuvant therapyXx_NEWLINE_xXParticipants must have a clinical indication for resection of metastatic melanoma; patients will be informed about other treatment options for stage IV melanoma including Braf inhibitors and antibodies to CTLA-4Xx_NEWLINE_xXPatients must be diagnosed with metastatic cytologically or histologically confirmed adenocarcinoma of the breast with HER2 over-expression or with newly diagnosed locally advanced (including inflammatory) breast cancer (LABC) with stage II-III disease; patients with metastatic (stage IV) disease (MBC) must have measurable lesionsXx_NEWLINE_xXParticipants must have histologically confirmed stage IIIA or IIIB non-squamous non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer [AJCC] 7th edition); patients with a clinical stage of IIIB are allowed only if they are thought to be a candidate for concurrent chemoradiationXx_NEWLINE_xXParticipants must have histologically confirmed stage IV non-small cell lung cancer (NSCLC) (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act [CLIA]-approved laboratoryXx_NEWLINE_xXParticipants with stage IV-V chronic kidney disease or end stage renal diseaseXx_NEWLINE_xXHas stage III or stage IV disease that is not surgically resectable.Xx_NEWLINE_xXHas received prior systemic chemotherapy/other targeted or biological antineoplastic therapy treatment for their Stage IV metastatic NSCLCXx_NEWLINE_xXHave histologically- or cytologically-confirmed unresectable stage III or stage IV melanoma not amenable to local therapyXx_NEWLINE_xXStage IV metastatic breast cancerXx_NEWLINE_xXBarcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage CXx_NEWLINE_xXParticipants must have histologically confirmed stage IV NSCLC (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act (CLIA)-approved laboratoryXx_NEWLINE_xXParticipants with stage V chronic kidney disease or end stage renal diseaseXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) (2009) stage IV melanoma, or stage III melanoma not curable by surgery and which is progressing; patients must have at least 1 target lesion measurable by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteriaXx_NEWLINE_xXHas stage III or stage IV disease that is not surgically resectable. Stage IIB (T3N0M0B0-1) cutaneous T cell lymphoma (CTCL) participants are eligible.Xx_NEWLINE_xXHas stage III or stage IV disease that is not surgically resectable. Stage IIB (T3N0M0B0-1) CTCL participants are eligible.Xx_NEWLINE_xXSubjects with stage IV non-small cell lung cancer as defined by American Joint Committee on Cancer (AJCC).Xx_NEWLINE_xXPatients with non-metastatic breast cancer are eligible; this includes American Joint Committee on Cancer (AJCC) 7th edition left- or right-sided breast cancer clinical or pathologic stage I, II, III or loco-regionally recurrent at time of diagnosis; for patients that receive neoadjuvant chemotherapy, AJCC 7th edition left- or right-sided breast cancer pathologic stage yp 0, I, II, III are eligibleXx_NEWLINE_xXDiagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junctionXx_NEWLINE_xXDiagnosed with Stage IV resectable diseaseXx_NEWLINE_xXParts A-C only: Patients must have biopsy proven MF, clinical stage I, II, or III (excluding visceral or nodal involvement), and must be refractory to or intolerant of established therapies for their conditionXx_NEWLINE_xXPathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLCXx_NEWLINE_xXHistological diagnosis of squamous or non-squamous, inoperable, stage 4 NSCLCXx_NEWLINE_xXHistologically confirmed Stage IV (metastatic) or unresectable Stage IIIc (locally advanced) melanomaXx_NEWLINE_xXHistologically confirmed unresectable stage III or stage IV melanoma (American Joint Committee on Cancer [AJCC] 7th edition classification); cutaneous melanoma and mucosal melanoma will be eligibleXx_NEWLINE_xXPatients must have histologically or cytologically confirmed breast cancer with stage IV or unresectable stage III diseaseXx_NEWLINE_xXMust meet criteria for high risk disease\r\n* Patients ? 365 days initially diagnosed with INSS stage 1 or 2 who progressed to a stage 4 without interval chemotherapyXx_NEWLINE_xXHas a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer [AJCC] 7th edition) squamous NSCLC.Xx_NEWLINE_xXPatients must have American Joint Committee on Cancer (AJCC) (2010) clinical stage T3-4, N0-1, M0 diseaseXx_NEWLINE_xXBiopsy-proven, previously untreated stage III or IV squamous cell carcinoma of the larynx, Primary tumor stage (T2, T3) and nodal stage (N0, N1, N2, N3).Xx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) (2009) stage IV cutaneous melanoma or stage III cutaneous or acral melanoma that is judged inoperable; patients with a history of uveal or mucosal melanoma are not eligibleXx_NEWLINE_xXHistologically-proven diagnosis of advanced (American Joint Committee on Cancer [AJCC], 7th addition: stage III or IV) or aggressive (published disease-specific survival rates less than 20% at 5 years following best currently available therapies) solid organ cancer; this includes but is not limit to: \r\n* Metastatic melanoma\r\n* Esophageal and gastric adenocarcinoma (stage III/IV)\r\n* Cholangiocarcinoma (any stage)\r\n* Pancreatic adenocarcinoma (any stage)\r\n* Gallbladder cancer (any stage)\r\n* Colorectal cancer (stage IV)\r\n* High-grade mucinous appendix cancer (any stage)\r\n* High-grade gastrointestinal neuroendocrine cancer (any stage)\r\n* Mesothelioma (any stage)\r\n* High-grade soft tissue sarcoma (any stage)Xx_NEWLINE_xXHistologically or cytologically documented Squamous or non-Squamous Non-small cell lung cancer (NSCLC) (Stage IIIB/IV), or recurrent or progressive disease following multimodal therapyXx_NEWLINE_xXAny T stage with ? N2 disease;Xx_NEWLINE_xXT4 disease, any N stage;Xx_NEWLINE_xXT3 Oral Cavity, any N stage; orXx_NEWLINE_xXDiagnosis of selected stage III or IVa/b head and neck squamous cell carcinoma (HNSCC); all patients must have T2-T4 primary tumors (patients with T1 tumors will be excluded); although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligibleXx_NEWLINE_xXARM 2 - A: Diagnosis of selected stage III or IVa/b HNSCC; all patients must have T2-T4 primary tumors (patients with T1 tumors will be excluded); although most of these patients will have regional nodal disease, patients with no nodal disease will also be eligibleXx_NEWLINE_xXCLL (Part 1): Rai Stage III or IV disease, or stage 0-II disease that meets National Cancer Institute Working Group (NCIWG) criteria for active disease requiring therapy that may include either of the following disease-related symptoms:Xx_NEWLINE_xXStage I, II, III, or IV disease; NOTE: stage I disease are eligible only if the disease is not amenable to external beam radiation therapyXx_NEWLINE_xXHistologic or cytologic diagnosis of cutaneous melanoma that is considered unresectable (stage III) or metastatic (stage IV); ocular and mucosal melanoma is excludedXx_NEWLINE_xXAnother previous or current invasive malignancy within the last 2 years, with the exception of curatively treated stage Ia cervical carcinoma, or resected stage Ia endometrial cancer, and noninvasive nonmelanoma skin cancers; patients with gBRCA1/2m and primary breast or ovarian cancers will be eligible for cohort 1Xx_NEWLINE_xXPatients must have stage III, IVa or IVb disease as determined by imaging studies and complete head and neck exam; staging evaluation should be in accordance with the American Joint Committee on Cancer Staging Manual, 7th editionXx_NEWLINE_xXHistologically or cytologically proven Stage IIb-IV melanoma (at diagnosis or at the time of recurrence) rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration; patients with treated brain metastases may be eligible if they meet the criteria. Small radiologic or clinical findings of an indeterminate nature will not be a basis for exclusion, and brain metastases will not be a basis for exclusion.\r\n* Staging of cutaneous melanoma will be based on the 7th edition American Joint Committee on Cancer (AJCC) staging system. Staging of mucosal melanomas will be based on the following system modified from the cutaneous melanoma staging system: 2.01- 4 mm primary with ulceration or > 4 mm primary = stage IIb, lymph node metastases = stage III, distant metastases = stage IV.Xx_NEWLINE_xXPathologically proven (either histologic or cytologic) diagnosis of NSCLC with any of the following stages (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition):\r\n* Stage IIIA or IIIB\r\n* Stage II NSCLC with medical contraindication to curative surgical resection\r\n* Stage IV disease with solitary brain metastasis that has been treated radically (eg: with surgical resection or stereotactic radiosurgery) and thoracic disease that would be classified as stage II-IIIXx_NEWLINE_xXUnresectable Stage III or Stage IV melanoma.Xx_NEWLINE_xXStage 1, 2, 3 or early and intermediate stage IVa (T1N0-2B, T2N0-2B) (level 2, non-matted) disease without evidence of distant metastases or extracapsular extension; primary site must be lateralized for a functional dissectionXx_NEWLINE_xXEvidence of distant metastases of stage IVXx_NEWLINE_xXMust have low, intermediate-risk or high-risk disease, defined as:\r\n* Low-risk: Embryonal, botryoid, spindle cell tumors only\r\n** Subset 1\r\n*** Stage 1, Group I, Group II\r\n*** Stage 1 Group III orbital only\r\n*** Stage 2, Group I, Group II\t\r\n** Subset 2\r\n*** Stage 1, Group III non orbit\r\n*** Stage 3, Group I, II\r\n* Intermediate-risk: Embryonal, botryoid, or spindle cell rhabdomyosarcoma (RMS)\r\n** Stage 2 or 3 and Group III\r\n** Alveolar, undifferentiated, or anaplastic RMS\r\n** Stage 1-3, group I-III\r\n* High-risk: Embryonal, botryoid, spindle cell, alveolar, undifferentiated, or anaplastic RMS with metastatic disease at diagnosis (stage 4)\r\n* Patients treated on RMS13 in the low or intermediate risk arm that experience disease progression prior to week 13 will transfer to the high risk arm and proceed with high risk chemotherapy starting at week 1 of the protocolXx_NEWLINE_xXPathologically proven (either histologic or cytologic) diagnosis of stage IIIA or IIIB non-small cell lung cancer; (according to American Joint Committee on Cancer [AJCC] staging, 7th edition) within 4 weeks of registration; the patient should have histologically or cytologically confirmed N2 diseaseXx_NEWLINE_xXPrior exposure to cetuximab in the metastatic (stage IV) settingXx_NEWLINE_xXAJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III.Xx_NEWLINE_xXClinical stage TIC or T2aXx_NEWLINE_xXMust meet stage II - III group criteria per AJCC Staging manual 7th edition.Xx_NEWLINE_xXHistologically confirmed early stage urothelial carcinoma of the bladder defined as Ta, T1, or Tis stage; tumor staging must be confirmed by TURBT performed within 42 days prior to registrationXx_NEWLINE_xXPhase I and expansion cohort: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with clinical stage: IV (see American Joint Committee on Cancer [AJCC] staging criteria, 7th edition) or stage IIB-IIIC (expansion cohort only)Xx_NEWLINE_xXHistological confirmation of ER negative breast carcinoma (defined as less than 10%), stage I, II, or IIIXx_NEWLINE_xXHas evidence of recurrent or metastatic (stage IV) breast cancerXx_NEWLINE_xXLymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade non-Hodgkin lymphoma (NHL) after initial therapy if stage III/IV in first partial response (PR1) or after progression if stage I/II < 1 year; stage III/IV patients are eligible after progression in CR/PRXx_NEWLINE_xXAll patients must be either stage IIIb/c or stage IV melanoma according to the American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed melanoma that is felt to be surgically unresectable in order to be eligible\r\n* All melanomas, except ocular/uveal melanoma, regardless of primary site of disease will be allowed; mucosal melanomas are eligible\r\n* Patients must not have received prior anticancer treatment for metastatic disease (for example, but not limited to, systemic, local, radiation, radiopharmaceutical)\r\n* Exceptions: Surgery for melanoma and/or post-resection brain radiotherapy (RT) if central nervous system (CNS) metastases and/or prior treatment with adjuvant IFN\r\n* All patients must have their disease status documented by a complete physical examination and imaging studies within 4 weeks prior to the first dose of study drug; imaging studies must include computerized tomography (CT) scan of neck, chest, abdomen, pelvis, and all known sites of resected disease in the setting of stage IIIb/c or stage IV disease, and brain magnetic resonance imaging ([MRI], brain CT allowable if MRI is contraindicated)\r\n* The complete set of baseline radiographic images must be available before treatment initiationXx_NEWLINE_xXSubjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) (8th edition) staging criteria:\r\n* AJCC stage IV (Tany, Nany, M1a(1), M1b(1), M1c(1) or M1d(1))\r\n* AJCC stage IIIC (at least N2b) or IIID with unresectable nodal/locoregional involvementXx_NEWLINE_xXDiagnosis of advanced/unresectable melanoma (American Joint Committee on Cancer [AJCC] v.8 stage 3C/D/4)Xx_NEWLINE_xXLocoregional disease with clinical stage of T1N1 or T2-3N0-2Xx_NEWLINE_xXPrior endoscopic mucosal resection (EMR) with a diagnosis of stage II or III esophageal cancer is eligible, irrespective of margin statusXx_NEWLINE_xXParticipants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the AJCC staging systemXx_NEWLINE_xXAnn Arbor stage II-IVXx_NEWLINE_xXHistory of end-stage renal disease requiring dialysisXx_NEWLINE_xXHistological or cytological confirmation diagnosis of stage 4 NSCLCXx_NEWLINE_xXPatients with histologically confirmed unresectable stage III or stage IV metastatic melanoma, who have not been previously treated with a SEMA4D antibody and have had prior anti-PD1/PDL1 inhibitors with documented progression; patient may have or not have prior anti-CTLA4 treatmentsXx_NEWLINE_xXInclusion Criteria Stage 1\n\n          -  ECOG Performance Status of 0 or 1\n\n          -  Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER,\n             and PR expression)\n\n          -  Radiologic/objective evidence of recurrence or disease progression after one line of\n             chemotherapy for metastatic breast cancer MBC\n\n          -  Availability of a representative tumor specimen that is suitable for determination of\n             PD-L1 and/or additional biomarker status via central testing\n\n          -  Eligible for capecitabine monotherapy\n\n          -  Adequate hematologic and end-organ function, laboratory test results, obtained within\n             14 days prior to initiation of study treatment.\n\n          -  Negative HIV test at screening\n\n          -  Negative hepatitis B surface antigen .\n\n          -  Negative hepatitis C virus (HCV) antibody test at screening or positive HCV antibody\n             test followed by a negative HCV RNA test at screening\n\n        Inclusion Criteria for Stage 1 and Stage 2\n\n          -  Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1\n             (RECIST v1.1)\n\n          -  Tumor accessible for biopsy\n\n          -  For patients receiving therapeutic anticoagulation: stable anticoagulant regimen\n             during the 14 days prior to initiation of study treatment\n\n          -  For women of childbearing potential: agreement to remain abstinent (refrain from\n             heterosexual intercourse) or use contraceptive measures as outlined for each specific\n             treatment arm\n\n          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use\n             contraceptive measures, and agreement to refrain from donating sperm, as outlined for\n             each specific treatment arm\n\n        Inclusion criteria stage 2\n\n          -  ECOG Performance Status of 0, 1, or 2\n\n          -  Patients randomly allocated to the control arm during Stage 1: ability to initiate\n             Stage 2 treatment within 3 months after experiencing unacceptable toxicity, provided\n             that Medical Monitor approval for entry into Stage 2 is obtained, or disease\n             progression per RECIST v1.1 while receiving control treatment\n\n          -  Patients randomly allocated to an experimental arm during Stage 1: ability to initiate\n             Stage 2 treatment within 3 months after experiencing unacceptable toxicity not related\n             to atezolizumab, disease progression per RECIST v1.1, or loss of clinical benefit as\n             determined by the investigator (see Section 3.1.1.1 for details) while receiving Stage\n             1 treatment\n\n          -  Availability of a tumor specimen from a biopsy performed upon discontinuation of Stage\n             1 (if deemed clinically feasible by the investigator)\n\n        Exclusion Criteria for Stage 1\n\n          -  Prior treatment with any of the protocol-specified study treatments\n\n          -  Treatment with investigational therapy within 28 days prior to initiation of study\n             treatment\n\n          -  Inability to swallow medication or malabsorption condition that would alter the\n             absorption of orally administered medications\n\n          -  Treatment with sorivudine or its chemically related analogues, such as brivudine\n\n          -  History of severe and unexpected reactions to fluoropyrimidine therapy\n\n        Exclusion Criteria for Stage 1 and Stage 2\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent\n             drainage procedures (once monthly or more frequently)\n\n          -  Uncontrolled tumor-related pain\n\n          -  Symptomatic, untreated, or actively progressing CNS metastases\n\n          -  History of leptomeningeal disease\n\n          -  Active or history of autoimmune disease or immune deficiency\n\n          -  History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis\n             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of\n             active pneumonitis on screening chest computed tomography (CT) scan History of\n             radiation pneumonitis in the radiation field (fibrosis) is permitted.\n\n          -  Active tuberculosis\n\n          -  Severe infection within 4 weeks prior to initiation of study treatment\n\n          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation\n             of study treatment\n\n          -  Significant cardiovascular disease\n\n          -  Prior allogeneic stem cell or solid organ transplantation\n\n          -  History of malignancy other than breast cancer within 2 years prior to screening, with\n             the exception of those with a negligible risk of metastasis or death\n\n          -  Treatment with systemic immunosuppressive medication (including, but not limited to,\n             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and\n             anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study\n             treatment, or anticipation of need for systemic immunosuppressive medication during\n             the course of the study\n\n          -  Pregnancy or breastfeeding, or intention of becoming pregnant during the studyXx_NEWLINE_xXHistologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated, with principal investigator (PI) confirmation; carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) 2009 stage I and stage II, with one of the following combinations of stage and grade:\r\n* Stage IA, grade 2, 3\r\n* Stage IB, grades 1-3\r\n* Stage II, grades 1-3Xx_NEWLINE_xXCervical carcinoma Stage 1B or lessXx_NEWLINE_xXConfirmed diagnosis of Stage III or Stage IV NSCLC and have received ? 1 line of prior systemic therapy in the locally advanced or metastatic settingXx_NEWLINE_xXStage IIIB/IV or recurrent non-small cell lung cancer which is not amenable to curative intent therapyXx_NEWLINE_xXPatients with advanced stage non-mycosis fungoides (MF) CTCL are eligible including, but not limited to, advanced stage lymphomatoid papulosis (LyP) or primary cutaneous anaplastic large cell lymphoma (pcALCL)Xx_NEWLINE_xXPatients who are concomitantly undergoing systemic therapy for more advanced stage disease are eligible.Xx_NEWLINE_xXStage IV (according to the American Joint Committee on Cancer [AJCC] 8th edition).Xx_NEWLINE_xXStage IV disease (metastatic or surgically unresectable, cT4b, N+, or M+ cancer)Xx_NEWLINE_xXNYHA classification of III or IVXx_NEWLINE_xXSubjects must have a clinical diagnosis of CTCL (mycosis fungoides), Stage IA, Stage IB, or Stage IIA.Xx_NEWLINE_xXClinical stage T2-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical stagingXx_NEWLINE_xXHas FIGO Stage IVBXx_NEWLINE_xXEligible tumors must meet one of the following criteria: Stage II or III, or T4, any N, M0, including clinical or pathologic inflammatory cancer or Regional Stage IV, where supraclavicular lymph nodes are the only sites metastasisXx_NEWLINE_xXParticipants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanomaXx_NEWLINE_xXHigh-intermediate risk disease, defined as:\r\n* T1-T3 N2 M0 or T3 N1 M0 or any stage III (T4 or N3) p16+ squamous cell carcinoma of the oropharynx (The American Joint Committee on Cancer [AJCC] 8th edition staging system)\r\n* T1-2 N1-3 M0 or T3-4 N0-3 M0 (stage III-IVB) p16+ squamous cell carcinoma of the hypopharynx or larynx\r\n* T1-2 N2-3 M0 or T3-4 N0-3 M0 (stage III-IVB) p16+ squamous cell carcinoma of the nasopharynx\r\n* Inoperable T4 N0-3 M0 (stage IVA-IVB) p16+ squamous cell carcinoma of the oral cavityXx_NEWLINE_xXPatients must have recurrent or metastatic HNSCC stage III/IV that is not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)Xx_NEWLINE_xXStage I-IIIA (stage I tumors must be >= 4 cm)Xx_NEWLINE_xXFinal American Joint Committee on Cancer (AJCC) version 7.0 stage 0-IIB (pathologic stage Tis, T1-T3, all must be N0 and M0 status)Xx_NEWLINE_xXPatients who have stage III-IV disease without distant metastases (M0) of 1) oral cavity, 2) larynx, 3) hypopharynx 4) oropharynx (human papillomavirus [HPV] negative [neg]) using American Joint Committee on Cancer (AJCC) 8th editionXx_NEWLINE_xXPatients who have oropharyngeal cancer that is HPV positive, stage II-III disease without distant metastases (M0) using AJCC 8th editionXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to curative local therapyXx_NEWLINE_xXHave unresectable (stage III) or advanced (stage IV) melanomaXx_NEWLINE_xXPelvic organ prolapse greater than stage IIXx_NEWLINE_xXParticipants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition proposed staging criteriaXx_NEWLINE_xXPatients with stage I-IVA are eligibleXx_NEWLINE_xXThe following tumor stage and Gleason scores: a) clinical >= stage T1c/T2 tumor with Gleason score >=8 b) clinical stage >= T2b tumor with Gleason score >= 7 and PSA > 10 ng/ml.Xx_NEWLINE_xXHistologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization [WHO] type 2a and 2b non-keratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registrationXx_NEWLINE_xXHave unresectable stage III or stage IV melanomaXx_NEWLINE_xXClinical stage T1-2, N0-1, or small volume N2b (American Joint Committee on Cancer [AJCC], 7th ed.), with no distant metastases, based on routine staging workup.Xx_NEWLINE_xXHave a histologic diagnosis of stage IV NSCLCXx_NEWLINE_xXClinical stage T1-T2, N1-N2b or T3, N1-N2b (American Joint Committee on Cancer [AJCC] 7th edition) with no distant metastases based on the following diagnostic workupXx_NEWLINE_xXStage 4 cancerXx_NEWLINE_xXEligibility for stage 2 of the study, if the extension stage is opened, will be determined by ribonucleic acid sequencing (RNAseq) analysis and master regulator profile of a single fresh needle biopsy specimen obtained during study screeningXx_NEWLINE_xXClinical stage T1c-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging prior to neoadjuvant chemotherapyXx_NEWLINE_xXPatients must have stage II-IV diseaseXx_NEWLINE_xXInoperable per local Investigator (Masaoka stage III or IV)Xx_NEWLINE_xXPatients must have received and failed or refused available therapy for unresectable/unresected Stage III or IV melanoma.Xx_NEWLINE_xXHigh-risk NB as defined as any of the following: \r\n* Stage 4 with MYCN amplification (any age)\r\n* Stage 4 without MYCN amplification (> 1.5 years of age)\r\n* Stage 3 with MYCN amplification (unresectable; any age)\r\n* Stage 4S with MYCN amplification (any age)Xx_NEWLINE_xXHistologically/cytologically documented stage IIIB to stage IV unresectable non-small cell lung cancer (either squamous cell carcinoma or non-squamous cell lung cancer or mixed histology; EGFR or ALK mutation excluded unless previously treated with a TKI)\r\n* Patients with adenocarcinoma must have been tested for EGFR and ALK mutationsXx_NEWLINE_xXFemale subjects with CA125-associated, advanced ovarian cancer (FIGO Stage III/IV) previously treated and now presenting with recurrent or persistent disease.Xx_NEWLINE_xXHistologically proven stage IV non-small cell lung cancerXx_NEWLINE_xXStage IA, IB, IIA, IIB, or IIIA (according to AJCC 7th edition). Patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumorXx_NEWLINE_xXHistory of another cancer within 3 years before enrollment with the exception of nonmelanoma skin cancers, or American Joint Committee on Cancer stage 0 or stage 1 cancer that has a remote probability of recurrence in the opinion of the investigator and the sponsor.Xx_NEWLINE_xXClinically stage I disease by American Joint Committee on Cancer (AJCC) 7th edition (N0, M0, T stages T1-T2a) or patients with stage T2bN0M0 disease (clinical stage IIA), as determined by a computed tomography (CT) chest, abdomen, pelvis or a positron emission tomography (PET) CT =< 60 days of treatment start, who are medically unfit for standard of care chemotherapy as documented by a medical oncologist or radiation oncologist, or who refuse standard of care chemotherapy as documented by a medical oncologist or radiation oncologistXx_NEWLINE_xXClinical stage I (breast tumor >= 1.0 cm in diameter), stage II or stage III breast cancer (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th Edition, 2010); multifocal disease is allowed if confined to 1 breast, as long as one tumor is at least 1 cm and meets all of the other inclusion criteriaXx_NEWLINE_xXUnresectable stage II, IIIA, or IIIB diseaseXx_NEWLINE_xXHistologically confirmed stage IV or recurrent non-small cell lung cancer (NSCLC) per the 7th International Association for the Study of Lung Cancer classification with squamous or non-squamous histologyXx_NEWLINE_xXStage T1N1/T2-4aN0-1 disease, as defined by American Joint Committee on Cancer (AJCC) criteria.Xx_NEWLINE_xXThere is no requirement nor restriction for prior therapy or stageXx_NEWLINE_xXStage I or selected stage IIa according to the 7th version of the International Association for the Study of Lung Cancer (IASLC) system: stage I (T1 or T2a [tumor size =< 5 cm] N0M0) stage IIa (T2 [tumor size > 5 cm but =< 7 cm] N0M0)Xx_NEWLINE_xXHistologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] version 7.0 Staging manual) NSCLCXx_NEWLINE_xXHistologically confirmed clinical or pathological stage 2 through stage 3c primary adenocarcinoma of the breastXx_NEWLINE_xXStage IA-IIIA NSCLC by 8th edition American Joint Committee on Cancer (AJCC) staging (that is deemed to be surgically resectable by a board certified thoracic surgeonXx_NEWLINE_xXStage IIIB or IV NSCLC as per 8th edition AJCC stagingXx_NEWLINE_xXPatients must have histologically or cytological confirmed stage IIIB or IV non-small cell lung cancerXx_NEWLINE_xXHistological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that is metastatic (Stage IV) and not amenable to resection with curative intent.Xx_NEWLINE_xXHistological or cytological evidence of stage IV non-small cell lung cancer (NSCLC) (any histology)Xx_NEWLINE_xXAll subjects must be either recurrent or stage IV American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed Merkel cell carcinoma with confirmed pathology in order to be eligibleXx_NEWLINE_xXClinical stage I-IVB (American Joint Committee on Cancer [AJCC], 7th edition); stages I-II glottic cancer are excludedXx_NEWLINE_xXStage I and II glottic carcinomaXx_NEWLINE_xXMetastatic (American Joint Committee on Cancer [AJCC] stage IV) RCCXx_NEWLINE_xXDisease eligibility and stage\r\n* Histologically confirmed diagnosis of melanoma, non-small cell lung cancer (NSCLC), or renal carcinoma\r\n* Previously treated or previously untreated stage IV melanoma, stage IV lung cancer, and metastatic renal cancer by American Joint Committee on Cancer (AJCC) staging criteria\r\n* Presence of a lesion that is suitable for hypofractionated radiotherapyXx_NEWLINE_xXPatients must have histologically confirmed, locally advanced or metastatic stage IV or non-resectable stage III non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients must have high-risk NB (MYCN-amplified stage 2/3/4/4S of any age and MYCN-nonamplified stage 4 in patients greater than 18 months of age)Xx_NEWLINE_xXRecurrent or persistent histologically proven locoregional OCSCC (recurrent T-stage 2-4) that was initially treated with surgery alone; to allow sufficient tumor tissue for the immunological analyses, patients with T-stage 1 OCSCC will be excludedXx_NEWLINE_xXDiagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapyXx_NEWLINE_xXHistologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapyXx_NEWLINE_xXFailure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapyXx_NEWLINE_xXNYHA classification of III or IVXx_NEWLINE_xXHistologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS); Phase 1: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; Phase 2: >= stage IB\r\n* Stage of disease according to TNMB classification\r\n* Pathology report must be diagnostic or be consistent with MF/SS criteria\r\n* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathological features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\r\n* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that has been recommended by the International Society of Cutaneous Lymphomas (ISCL) should be usedXx_NEWLINE_xXAny patient eligible for internal implantation without MR guidance will be considered eligible for this protocol; standard criteria for internal implantation include:\r\n* Carcinoma of the cervix: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the uterus: stage IIIB (vaginal involvement), inoperable, or vaginal recurrence\r\n* Carcinoma of the vagina: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the vulva: stage I-IVA or recurrence\r\n* Carcinoma of the urethra based on treating physician’s discretionXx_NEWLINE_xXClinical or pathologic stage Stage III-IVb per the American Joint Committee on Cancer (AJCC), 7th edition.Xx_NEWLINE_xXStage I or II; T1N1 and T2N1 stage III presentations per AJCC 7th editionXx_NEWLINE_xXSubjects who are ipilimumab naive with progressive unresectable stage III or stage IV melanoma; eligible patients may have had prior adjuvant therapy, but not including ipilimumab, and been treated with up to 3 prior treatments for metastatic melanoma (eg, chemotherapy, other biologic or targeted therapy or IL-2)Xx_NEWLINE_xXHistologic or cytologic confirmation of stage III or stage IV melanomaXx_NEWLINE_xXStage at least T2 or greaterXx_NEWLINE_xXHave pathologically confirmed diagnosis of advanced NSCLC (stage IIIB or stage IV, as defined by the American Joint Committee on Cancer staging system-TNM 7th edition, 2010)Xx_NEWLINE_xXPresumed American Joint Committee on Cancer (AJCC) tumor stage I or IIXx_NEWLINE_xXAJCC stage III/IV differentiated thyroid cancerXx_NEWLINE_xXStage 3 or 4 disease without evidence of distant metastasesXx_NEWLINE_xXPathologically confirmed unicentric invasive breast cancer defined as radiologic clinical stage T1 or T2 (=< 5 cm), N0 or N1 (=< 4 abnormal axillary nodes on initial ultrasound), clinical stage M0Xx_NEWLINE_xXHave Barcelona Clinic Liver Cancer (BCLC) stage C disease or BCLC stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approachXx_NEWLINE_xXMust have clinically node negative stage I (T1N0) or stage II (T2N0) breast cancer\r\n* Preoperative ultrasound of the axilla with biopsy of suspicious nodes is recommended as clinically indicated per the discretion of the treating physicianXx_NEWLINE_xXHistologically or cytologically confirmed advanced (stage 4, according to the American Joint Committee on Cancer [AJCC] staging manual) NSCLCXx_NEWLINE_xXProgressing based on organ assessment after at least 3 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD, ORXx_NEWLINE_xXPathologically-confirmed invasive breast cancer; if patients undergo upfront surgery, the pathologic stage must be T0-T3, N0-N2a or N3a; if patients receive neoadjuvant chemotherapy prior to surgery, the clinical stage must be T0-T3, N0-N2a or N3aXx_NEWLINE_xXHistologically confirmed metastatic melanoma (stage IV) or unresectable stage III; patients with BRAF or BRAF-wild-type are eligible; only BRAF V600 mutated melanoma will be eligible for the triplet arm while BRAF-wild-type or NRAS-mutated melanoma will be eligible for the doublet armXx_NEWLINE_xXHistological or cytological confirmation of colorectal cancer (CRC) with available tissue, currently stage IVXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IIIB or IV (American Joint Committee on Cancer, 7th edition; AJCC 7) non-small cell lung cancerXx_NEWLINE_xXStage IV disease, if the metastatic sites are not amendable for local therapy (i.e. radiation and/or surgery), and are not candidates for breast surgery will not be eligibleXx_NEWLINE_xXHistologically diagnosed or cytologically proven advanced or metastatic NSCLC patients, either Stage IIIB/Stage IV disease (according to Version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or recurrent disease following radiation therapy or surgical resection;Xx_NEWLINE_xXSubjects must have histologically or cytologically-documented stage IIIB or stage IV, recurrent, or metastatic non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) stage 3 or 4 histologically proven NSCLC not amenable to curative therapyXx_NEWLINE_xXClinical stage IV cancerXx_NEWLINE_xXClinical stage IB (>= 3 cm per computed tomography [CT]), stage IIA/IIB, or stage IIIA (N0-2) amenable to surgical resectionXx_NEWLINE_xXPatients who have unresectable stage III through stage IV metastatic melanoma that have not received prior PD-1 directed therapy (Arm A) or that have progressed despite prior PD-1 directed therapy (Arm B)Xx_NEWLINE_xXa diagnosis of stage I, II, or III breast cancer;Xx_NEWLINE_xXStage 0 or Stage IV BCXx_NEWLINE_xXPatients with T stage T1-3Xx_NEWLINE_xXPatients with N stage N0-N2cXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7) non-small cell lung cancerXx_NEWLINE_xXSubjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Act (CLIA) certified laboratory, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria:\r\n* AJCC stage IV (T any, N any, M1a, b, or c)\r\n* AJCC stage IIIB or IIIC with unresectable nodal/locoregional involvementXx_NEWLINE_xXPatients must have stage IV melanoma, with newly identified brain or spine metastasesXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) clinical stage T2-T3 N0M0Xx_NEWLINE_xXIs on anticoagulation that cannot be discontinued in the perioperative stageXx_NEWLINE_xXMeasurable, unresectable stage III (in transit lesions) or stage IVA, IVB or IVC diseaseXx_NEWLINE_xXHas clinical stage T2-T4a N0/X M0 urothelial carcinoma; clinical T stage is based on the pre-study standard of care transurethral resection of the bladder tumor (TURBT) sample and imaging studiesXx_NEWLINE_xXPatient's disease state must be American Joint Committee on Cancer (AJCC) 7th edition stage I-IIIXx_NEWLINE_xXAppropriate staging studies identifying as American Joint Committee on Cancer (AJCC) stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or lessXx_NEWLINE_xXT2 (> 3.0 cm), T3, stage III, or stage IV breast cancerXx_NEWLINE_xXLymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 yearXx_NEWLINE_xXHistologically or cytologically proven diagnosis of NSCLC that is locally advanced (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the 7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International Union Against Cancer and the American Joint Committee on Cancer.Xx_NEWLINE_xXPatients must have unresectable cutaneous, mucosal or ocular metastatic stage III/IV melanoma, and in the opinion of the institutional principal investigator (PI) is an acceptable candidate for adoptive cell therapy (ACT) with high dose interleukin-2 (IL-2); patients with ocular or mucosal metastatic melanoma may be included, as our prior experience indicates that TIL can be successfully propagated from these subtypes of melanoma metastasesXx_NEWLINE_xXHigh-risk NB as defined by risk-related treatment guidelines' and the International NB Staging System, i.e., stage 4 with (any age) or without (> 365 days of age) MYCN amplification, MYCN-amplified stage 3 (unresectable; any age), or MYCN-amplified stage 4SXx_NEWLINE_xXHave a histologic or cytologic diagnosis of stage IV NSCLCXx_NEWLINE_xXRadiographically confirmed endometrial adenocarcinoma of stages III-IV requiring adjuvant therapy; if stage III disease is suspected, there should be multiple pelvic and/and or lymph nodes involvedXx_NEWLINE_xXRadiographic imaging demonstrating uterine cancer that is probably stage I or IIXx_NEWLINE_xXPatients with MF/SS must have stage IB, IIA, IIB, III or IV disease; patients with primary cutaneous CD30-positive lymphoproliferative disorder must have multifocal symptomatic or extensive lesions requiring systemic treatmentXx_NEWLINE_xXParticipants with age greater than or equal to (>=) 18 years with either unresectable Stage IIIC or Stage IV metastatic melanoma positive for the BRAF V600 mutation, or other malignant tumor types that harbor a V600-activating mutation of BRAFXx_NEWLINE_xXDiagnosed with stage III colon or stage II/III rectal cancer that will receive neoadjuvant or adjuvant chemotherapy but have not yet startedXx_NEWLINE_xXColon cancer stages I-II and IV or rectal cancer stage I or IVXx_NEWLINE_xXPatients with a history of stage IV or metastatic diseaseXx_NEWLINE_xXStage III or stage IV metastatic melanoma as defined on imaging studies performed within 28 days of first dose of pembrolizumab and clinical exam performed within 14 days of first dose of pembrolizumabXx_NEWLINE_xXCAPMATINIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteriaXx_NEWLINE_xXCERITINIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteriaXx_NEWLINE_xXREGORAFENIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteriaXx_NEWLINE_xXENTRECTINIB INCLUSION CRITERIA: Unresectable stage III or stage IV melanoma by clinical or radiographic criteriaXx_NEWLINE_xXHave TNM clinical stage III, IVA, or IVB diseaseXx_NEWLINE_xXPatients with TNM Stage IVC diseaseXx_NEWLINE_xXBiopsy proven HNSCC of the oropharynx, larynx, hypopharynx, or oral cavity stage III-IVB as defined by American Joint Committee on Cancer (AJCC) T0 - T4, N0 - N3, M0Xx_NEWLINE_xXBiopsy-confirmed CD4+ mycosis fungoides or Sézary syndrome, stage IB to IIIBXx_NEWLINE_xXPatients must have pathologic diagnosis of adenocarcinoma or large cell carcinoma of the lung with confirmation by immunohistochemistry (e.g., transcription termination factor 1 [TTF-1] positivity) (histologic tissue diagnosis is recommended, but cytology is acceptable); stage IIIA/IIIB or oligometastatic stage IV in which the patient is still considered an appropriate candidate for aggressive chemoradiotherapy for the primary tumor; oligometastatic disease is defined as =< 5 metastatic sites (=< 3 lesions per organ); for intracranial metastasis, the patient should have asymptomatic disease that is stable on steroids or 1 to 3 symptomatic metastatic lesions treated with stereotactic radiosurgery (SRS)Xx_NEWLINE_xXStage at diagnosis T2 through T4a-c, N0 through N2, and M0; patients with inflammatory breast cancer or metastatic disease at diagnosis will be excluded; patients with multicentric, multifocal, and/or bilateral disease are allowed to participate so long as all tumors meet the histologic criteria of the studyXx_NEWLINE_xXPrior use of platinum or paclitaxel for stage IV non-small cell lung cancer (NSCLC) or concurrent use of other anticancer approved or investigational agentsXx_NEWLINE_xXPatients must be classified post-operatively as Stage IB, II or IIIA on the basis of pathologic criteria.Xx_NEWLINE_xXStage IIIB or IV NSCLC (any histology) at the time of study entryXx_NEWLINE_xXHistologically or cytologically confirmed unresectable locally advanced (Stage IIIB) or metastatic (Stage IV) NSCLC.Xx_NEWLINE_xXHistory of another invasive cancer within 5 years with the exceptions of nonmelanoma skin cancers and American Joint Committee on Cancer (AJCC) stage 0 or 1 cancers that have a remote probability of recurrence in the opinion of the investigatorXx_NEWLINE_xXPatients with a diagnosis of cytologically or histologically documented adenocarcinoma of the lung with either metastatic disease (stage IV), Stage IIIB or Stage IIIC disease not amenable to surgery with curative intentXx_NEWLINE_xXAJCC stage III or IV completely resectable melanoma identified before surgeryXx_NEWLINE_xXMust not have had prior systemic therapy for stage IV RCC (except for nivolumab as part of part A of this protocol)Xx_NEWLINE_xXStage IIIB-IV, locally advanced or metastatic disease according to the 7 th edition of the AJCC lung cancer TNM classification systemXx_NEWLINE_xXAll patients with Surgical Stage III or IVA endometrial carcinoma per FIGO 2009 staging criteria, including clear cell and serous papillary and undifferentiated carcinomas.Xx_NEWLINE_xXPatients with FIGO 2009 Stage IVB endometrial cancer.Xx_NEWLINE_xXPatients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal diseaseXx_NEWLINE_xXPatients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer (NSCLC) (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)Xx_NEWLINE_xXPatients with metastatic, surgically unresectable melanoma or newly diagnosed melanoma patients of any stage unable to receive or complete standard therapyXx_NEWLINE_xXInsufficient breast imaging to judge clinical stageXx_NEWLINE_xXInsufficient breast imaging to judge clinical stageXx_NEWLINE_xXClinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 diseaseXx_NEWLINE_xXClinical stage N0, M0Xx_NEWLINE_xXClinical stage IV invasive mammary carcinomaXx_NEWLINE_xXMedically unresectable (stage I-II) or locally advanced (stage III); patients with distant metastases (stage IV) must have stable disease or improved disease (partial response, or complete response) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria as determined on serial imaging following a course of chemotherapyXx_NEWLINE_xXHistologically confirmed diagnosis of locally advanced STS that is unresectable with clear wide margins, for which preoperative radiotherapy is considered appropriate\r\n* Examples:\r\n** Resectable stage IIB, III, and IV disease that are not suitable for surgically resection alone due to inability to achieve clear margins\r\n** Including metastatic (stage IV) disease for which radiotherapy and surgical resection are indicated\r\n** Except certain histologic subtypes: gastrointestinal stromal tumor (GIST), Desmoid, Ewing sarcoma, Kaposi sarcoma, and bone sarcomasXx_NEWLINE_xXStage IV metastatic disease (only during the phase II)Xx_NEWLINE_xXThe subject must have clinical stage III or resectable stage IV MEL; subject’s may not have a diagnosis of uveal or mucosal melanomaXx_NEWLINE_xXHas stage IV or recurrent disease that has been treatedXx_NEWLINE_xXHistologic diagnosis of either limited stage SCLC (LS-SCLC), or extensive stage SCLC (ES-SCLC) or neuroendocrine tumorXx_NEWLINE_xXIndividuals with stage IIIB or IV, unresectable non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for stage IIIB or IV disease, and who are not candidates for curative surgery or radiation therapyXx_NEWLINE_xXFor cohort 1: early stage MF (low or intermediate 1 stage as defined by Dynamic International Prognostic Scoring System [DIPSS]) without currently available treatment optionsXx_NEWLINE_xXAdvanced stage non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXEnd-stage renal disease (i.e., any patient requiring or advised to undergo dialysis)Xx_NEWLINE_xXDocumented history of clinical stage IV (any T, any N, M1a/b) disease as per American Joint Committee on Cancer (AJCC) staging system 7th editionXx_NEWLINE_xXStage IV cancer by American Joint Committee on Cancer (AJCC) staging criteria (except for pancreatic cancer cohort)Xx_NEWLINE_xXStage IV non-small cell lung cancer or recurrent disease which cannot be approached with curative intentXx_NEWLINE_xXBarcelona Clinic Liver Cancer stage B or C; segmental and subsegmental portal vein thrombosis is allowedXx_NEWLINE_xXPatients must be classified post-operatively as Stage IB (? 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).Xx_NEWLINE_xXClinical American Joint Committee on Cancer (AJCC) stage (7th edition) IIA-IIIB NSCLC (T1-4N0-3M0)Xx_NEWLINE_xXStage - NSCLC with primary resection option for potential cure, as assessed by a faculty surgeon at SKCCC or MSKCC; this may include clinical stage IB (>= 4 cm), II and IIIA; subjects with N3 nodal involvement are not includedXx_NEWLINE_xXSubjects will be required to agree to a biopsy performed at baseline and again at week 8 of the study in order to be eligible for enrollment in stage 1 of the studyXx_NEWLINE_xXPatients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIICXx_NEWLINE_xXT-2 (> 3.0 cm), T-3, stage III, or stage IV breast cancerXx_NEWLINE_xXClinical stage a =< T1-2a (American Joint Committee on Cancer [AJCC] 7th edition)Xx_NEWLINE_xXPatients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have:\r\n* No evidence of disease (NED), or \r\n* Stable bone only diseaseXx_NEWLINE_xXPreviously untreated stage IV lung adenocarcinoma confirmed at the Memorial Sloan-Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXHistological/cytologically documented primary International Federation of Gynecology and Obstetrics (FIGO) stage 3C1, 3C2, stage 4A, and 4B uterine serous carcinoma; in addition, certain stage 3A and B disease are also allowed\r\n* Residual disease after primary surgery:\r\n** Eligible:\r\n*** Stage 3A and B (pelvic, but confined to adnexa or vagina), residual disease present\r\n*** Stage 3CI (pelvic node positive)\r\n*** Stage 3CII (para-aortic node positive)\r\n*** Stage 4A (bladder or pelvic bowel)\r\n*** Stage 4B (distant metastases [mets] including abdominal mets), completely resected\r\n** Not eligible\r\n*** Stage 3A and B (pelvic, but confined to adnexa or vagina), completely resected\r\n*** Stage 4B (distant mets including abdominal mets), residual disease presentXx_NEWLINE_xXPathologically confirmed stage pT1-T3, pN0, M0 diseaseXx_NEWLINE_xXHistological/cytological diagnosis of melanoma. AJCC stage IV (any T, any N, M1), metastatic, progressive, refractory, melanoma.Xx_NEWLINE_xXPatients may have advanced unresectable stage IV disease, resectable stave IV disease or recently resected stage IV disease (<10 weeks prior) with no apparent disease.Xx_NEWLINE_xXPathologically proven (either histologic or cytologic) diagnosis of stage IV or recurrent non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)Xx_NEWLINE_xXThe patient has newly-diagnosed, biopsy proven squamous cell carcinoma of stage I-IV (T1-3, N0-2b) of the oropharynxXx_NEWLINE_xXAnn Arbor stage I - stage IV DLBCL at the time of relapsed/refractory disease to be eligibleXx_NEWLINE_xXPatients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal disease (Turnstile I)Xx_NEWLINE_xXDiagnosed with stage I-IV breast cancerXx_NEWLINE_xXPatients must have histologically confirmed adenocarcinoma of the breast associated with the following clinical stage: IIA, IIB, IIIA, IIIB, or IIIC; patients with stage IV disease are also eligible if there is an intention to perform breast surgery after neoadjuvant therapy is completed, or in patients participating in clinical trials where surgery after neoadjuvant therapy may be an option (eg. E2108)Xx_NEWLINE_xXHistologically confirmed stage III colorectal cancer as determined by American Joint Committee on Cancer (AJCC) 7th editionXx_NEWLINE_xXEligible patients will have a histologic or cytologic diagnosis of NSCLC of the advanced stage (IV), with no known curative treatment optionsXx_NEWLINE_xXPatients with resectable primary NSCLC who are undergoing surgery to resect T3 to T4 lesions OR any patients with clinical NI or N2 disease regardless of T-stageXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) T1 or T2; N0 or N1microscopic (mic); stage IA-IIA breast cancerXx_NEWLINE_xXPatients with stage IB or II cutaneous melanomaXx_NEWLINE_xXPatients must have documented, clinically measurable 7th edition American Joint Committee on Cancer (AJCC) stage IIIB/C (bulky nodal and/or in transit disease) or stage IV (distant metastatic) melanoma; patients with brain metastases that have been appropriately treated with surgical resection and/or radiation are eligible for inclusion if they meet the performance status and life expectancy criteria; patients who are BRAF V600E mutation positive need to have failed, refused, or be ineligible for at least 2 lines of therapy (vemurafenib plus one other regimen)Xx_NEWLINE_xXA history of AJCC stage IIIB/C or stage IV melanoma but no current clinical evidence of metastatic diseaseXx_NEWLINE_xXPatients must have metastatic melanoma or stage III in-transit, subcutaneous, or regional nodal disease (Turnstile I)Xx_NEWLINE_xXStage IV (American Joint Committee on Cancer [AJCC]) breast cancer patients who have failed at least one conventional therapy for metastatic diseaseXx_NEWLINE_xXDisease must be stage III or IVXx_NEWLINE_xXPatient must have a medical oncology consult and be recommended to receive or are currently receiving neoadjuvant chemotherapy for a stage IIB through IV carcinomaXx_NEWLINE_xXFIGO stage 3A diseaseXx_NEWLINE_xXPrior endoscopic mucosal resection (EMR) with a diagnosis of stage II-III esophageal cancer is eligibleXx_NEWLINE_xXNewly diagnosed patients with stage I and II follicular lymphoma, pathologically confirmed at MD Anderson Cancer Center (MDACC) to be grade 1 or 2Xx_NEWLINE_xXEarly stage IB-IIIA, operable non-small cell lung cancer, confirmed in tissueXx_NEWLINE_xXAdvanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American Association for the Study of Liver Disease [AASLD] guidelines)Xx_NEWLINE_xXPatients with advanced melanoma defined as unresectable stage III or metastatic stage IV disease. Patients with acral or mucosal melanoma or patients with unknown primary melanoma are acceptable in Phase 1b but are excluded from Phase II. Patients with uveal melanoma are excluded from the study.Xx_NEWLINE_xXCervical carcinoma stage 1B or lessXx_NEWLINE_xXAnn Arbor stage I or II diseaseXx_NEWLINE_xXPatients must have a pathologically confirmed diagnosis, either at MSKCC or at the participating site, of stage I-III malignant pleural mesotheliomaXx_NEWLINE_xXSubjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0-1 being eligible; and have a primary tumor of the pancreas (i.e., pancreatic head, neck, uncinate process, body/tailXx_NEWLINE_xXThe patient must have stage 0, I, or II breast cancer; if stage II, the tumor size must be 3 cm or lessXx_NEWLINE_xXT2 (> 3.0 cm), T3, stage III, or stage IV breast cancerXx_NEWLINE_xXHave a history of surgically resected and pathologically proved American Joint Committee on Cancer (AJCC) stage I or stage II adenocarcinoma of the head, neck, or uncinate of the pancreasXx_NEWLINE_xXStage IIIA or Potentially resectable superior sulcus tumorsXx_NEWLINE_xXHistologically-documented high-risk endometrioid adenocarcinoma with no visible residual disease, defined by the following criteria:\r\n* Surgical stage I disease with < 50 myometrial invasion and grade 3 tumor (IAG3) with lymphovascular space involvement;\r\n* Surgical stage I disease with >= 50% myometrial invasion and grade 2 or 3 tumor (IBG2, IBG3);\r\n* Any surgical stage II disease (II);\r\n* Any surgical stage III disease (IIIA, IIIB, IIIC); and\r\n* Any surgical stage IV disease with no residual macroscopic tumorXx_NEWLINE_xXClinical stage T1b-T2b, N0-Nx, M0-Mx (American Joint Committee on Cancer [AJCC] 6th Edition)\r\n* T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, computed tomography [CT], and/or magnetic resonance imaging [MRI])\r\n* M-stage determined by physical exam, CT or MRI; bone scan not required unless clinical findings suggest possible osseous metastasesXx_NEWLINE_xXPatients must have measurable or evaluable Stage IV breast cancerXx_NEWLINE_xXHigh-risk NB as defined by risk-related treatment guidelines and the International NB Staging System, i.e., stage 4 with (any age) or without (> 18 months old) myelocytomatosis viral related oncogene (MYCN) amplification, MYCN-amplified stage 3 (unresectable; any age), MYCN-amplified stage 4S, or disease resistant to standard chemotherapyXx_NEWLINE_xXMDS at any stage; prior therapies allowedXx_NEWLINE_xXPatients must have metastatic melanoma, uveal melanoma or stage III in-transit or regional nodal disease (Turnstile I)Xx_NEWLINE_xXLymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 yearXx_NEWLINE_xXPathological and radiographic documented stage IIIB/IV NSCLC (squamous, adenocarcinoma, bronchioloalveolar, large cell, undifferentiated or not otherwise specified non-small cell carcinoma) diagnosed less than two months prior to randomization. Patients must have ECOG performance status of 0-1 and life expectancy >3 months.Xx_NEWLINE_xXPatients with any stage of disease will be eligibleXx_NEWLINE_xXStage IV diseaseXx_NEWLINE_xXHave histologically proven diagnosis of: non-small cell lung cancer (NSCLC) (stage I, II, or IIIa)Xx_NEWLINE_xXStage IIIbXx_NEWLINE_xXLymphoblastic lymphoma, Burkitt’s lymphoma, and other high-grade NHL after initial therapy if stage III/IV in CR1/PR1 or after progression if stage I/II < 1 yearXx_NEWLINE_xXPatients who have received previous treatment for metastatic or stage IV diseaseXx_NEWLINE_xXPatients with biopsy-proven adenocarcinoma, stage II- IV rectal cancer.Xx_NEWLINE_xXMayo stage II or IIIaXx_NEWLINE_xXInclusion Criteria:\n\n        Each participant must meet all the following inclusion criteria to be enrolled in the\n        study:\n\n          1. Histologically confirmed CD30+ classical HL.\n\n          2. Advanced stage, newly diagnosed HL (Stage III and Stage IV disease).\n\n          3. Treatment-naive HL.\n\n          4. Have performance scores of greater than or equal to (>=) 50 for Lansky\n             Play-performance or Karnofsky Performance Status.\n\n        Exclusion Criteria:\n\n          1. Nodular lymphocyte predominant HL.\n\n          2. Known active cerebral/meningeal disease, including signs or symptoms of progressive\n             multifocal leukoencephalopathy (PML) or any history of PML.\n\n          3. Any sensory or motor peripheral neuropathy.\n\n          4. Symptomatic neurologic disease compromising normal activities of daily living or\n             requiring medications.Xx_NEWLINE_xXNew diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.Xx_NEWLINE_xXHistologic diagnosis of stage IV metastatic melanoma, with 1 melanoma lesion that can be safely irradiated in the opinion of the radiation oncologist (note: subjects with primary ocular and mucosal melanoma are permitted). Lesions may include, but are not limited to:Xx_NEWLINE_xXAnn Arbor Stage II, III or IVXx_NEWLINE_xXPatients must have a histologically or cytologically confirmed, unresectable, advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLCXx_NEWLINE_xXStage IV (metastatic) disease.Xx_NEWLINE_xXParticipants must have histologically confirmed unresectable stage III or stage IV melanomaXx_NEWLINE_xXTreatment of unresectable stage III or stage IV melanoma with a tyrosine kinase inhibitor within prior 4 months; sorafenib for purposes of eligibility will not be considered acceptable prior therapyXx_NEWLINE_xXMore than 3 prior systemic therapies for unresectable stage III or stage IV melanomaXx_NEWLINE_xXPatient with histologically or cytologically confirmed non-resectable or metastatic stage 3 (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage 4 melanomaXx_NEWLINE_xXStage IV diseaseXx_NEWLINE_xXSignificant medical disease other than Stage IV breast cancerXx_NEWLINE_xXStage 3 or 4 disease without evidence of distant metastasesXx_NEWLINE_xXStage I-III (according to ENSAT classification 2008; see Appendix 2)Xx_NEWLINE_xXScheduled to undergo immediate, post-mastectomy, tissue assisted breast reconstruction, Reconstruction shall be either one-stage (direct-to-implant) or two-stage, unilateral or bilateral, prophylactic or therapeuticXx_NEWLINE_xXSubjects must have either stage IV breast or ovarian cancer in remission or with stable disease on trastuzumab monotherapyXx_NEWLINE_xXStage IV pathologically proven NSCLC.Xx_NEWLINE_xXHas a histologically- or cytologically-confirmed diagnosis of Stage IV (American Joint Committee on Cancer [AJCC] v 8) NSCLC and has not had prior systemic therapy for advanced diseaseXx_NEWLINE_xXPatients with histologically or cytologically documented squamous or non-squamous NSCLC with stage IIIB or stage IV disease, who received no prior systemic treatment for recurrent or metastatic NSCLCXx_NEWLINE_xXStage IV breast cancerXx_NEWLINE_xXPatient with disease (stage) eligible per cohortXx_NEWLINE_xXRai stage 0 - II without active disease according to IWCLL 2008 criteriaXx_NEWLINE_xXStage IV (metastatic) diseaseXx_NEWLINE_xXBiopsy-proven, primary or recurrent advanced-stage (III/IV) cutaneous squamous cell carcinoma of the head and neck.Xx_NEWLINE_xXHistologically confirmed cutaneous T-cell non-Hodgkin lymphoma (CTCL) per World Health Organization (WHO) classification 2016 including, mycosis fungoides (MF) or Sezary syndrome (SS); phase 1 : >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF; expansion cohort: >= stage IB\r\n* MF/SS stage of disease according to TNMB classification\r\n* SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic skin may only reveal suggestive but not diagnostic histopathologic features, the diagnosis may be based on either node biopsy or fulfillment of B2 criteria\r\n* For MF where the histological diagnosis by light microscopic examination is not confirmed, diagnostic criteria that been recommended by the International Society for Cutaneous Lymphomas (ISCL) should be usedXx_NEWLINE_xXPatients must be appropriate candidates for at least 2 cycles of ABVD or AVD (this could include patients ranging from favorable risk early stage disease to poor prognosis advanced stage disease)Xx_NEWLINE_xXStage IV or metastatic/recurrent non-small cell lung cancer; for expansion cohorts, patient’s tumor must also harbor a KRAS mutation detected in a CLIA certified laboratoryXx_NEWLINE_xXHave stage IV, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC) with progressive disease after platinum containing chemotherapy (EGFR mutant, ALK, or ROS-1 rearranged NSCLC must have progressed on prior approved tyrosine kinase inhibitor [TKI]’s)Xx_NEWLINE_xXClinical stage II or stage III (by American Joint Committee on Cancer [AJCC] 7th edition) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goalXx_NEWLINE_xXTis-T3 Urothelial cancer; patients will be stratified according to clinical stageXx_NEWLINE_xXPathological stage I-IVa HNSCCXx_NEWLINE_xXStage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer [AJCC] criteria) not amenable to local therapyXx_NEWLINE_xXAdvanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCCXx_NEWLINE_xXCervical carcinoma of Stage 1B or less.Xx_NEWLINE_xXHistologically confirmed locally advanced unresectable (stage III) or stage IV pancreatic ductal adenocarcinoma (PDAC)Xx_NEWLINE_xXIntermediate-risk group: Oropharynx cancer that is p16-positive by immunohistochemistry with smoking status > 10 Pack-years, stage T1-2N2b-N3 OR ? 10 pack-years, stage T4N0-N3 or T1-3N3.Xx_NEWLINE_xXPatients must have unresectable stage III or stage IV melanoma; patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressiveXx_NEWLINE_xXDiagnosis of stage IV melanomaXx_NEWLINE_xXParticipants must have presented at initial diagnosis with extensive-stage disease (defined as stage IV [T any, N any, M1a/b] per National Comprehensive Cancer Network [NCCN] guidelines version 1.2015, American Joint committee on Cancer [AJCC] staging manual, seventh [7th] edition, 2010)Xx_NEWLINE_xXHistologically confirmed diagnosis of non-small cell lung cancer (NSCLC); patients should have stage IV disease (American Joint Committee on Cancer [AJCC] 7th edition), stage IIIb disease that is not amenable to potentially curative treatment (e.g. chemoradiotherapy) or unequivocal progression in a prior irradiated field; measurable or evaluable disease is requiredXx_NEWLINE_xXStage IVA-B disease of 1) oral cavity, 2) oropharynx, 3) larynx, 4) hypopharynxXx_NEWLINE_xXSubjects must have one of the following risk factors:\r\n* Prostate-specific antigen (PSA) >= 20 and/or\r\n* Gleason score >= 8 and/or\r\n* Clinical or radiographic stage >= T3a per American Joint Committee on Cancer (AJCC) 7th Edition Staging Manual and/or\r\n* Radiographic pelvic lymph node positive disease and/or\r\n* At least two out of four of the following: PSA 10-19.9, Gleason score (GS) = 3+4, clinical stage = T2b/T2c, >= 50% positive biopsy coresXx_NEWLINE_xXFOR PATIENTS IN STAGE 1 (PATIENTS #1-#17)Xx_NEWLINE_xXFOR PATIENTS IN STAGE 2 (ENROLLED PATIENT #18 AND BEYOND)Xx_NEWLINE_xXSTAGE IXx_NEWLINE_xXPathologic diagnosis of stage IB2-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous or adenocarcinoma of the vulva that is not amenable to curative surgical resection aloneXx_NEWLINE_xXStage IV diseaseXx_NEWLINE_xXVisceral aGVHD defined as: at least stage III/IV acute liver or stage II/III gastrointestinal (GI) GVHD by clinical criteria and/or GI and/or liver biopsy confirmation showing no alternative explanation for symptoms of GVHDXx_NEWLINE_xXPatients must have American Joint Committee on Cancer (AJCC) stage IIIC unresected or IV diseaseXx_NEWLINE_xXStage III/IVa/b squamous cell carcinoma (SCC) by American Joint Committee on Cancer (AJCC) 7 criteria (advanced, but not metastatic)Xx_NEWLINE_xXMelanoma cohort only: histologic proof of surgically unresectable stage IV malignant melanomaXx_NEWLINE_xXPathologically confirmed, clinically evident (by physical examination or radiographic imaging) stage IIIB, IIIC, and IV M1a and b cutaneous melanoma (anatomic stages T1-4b N1a and T1-4b N2a not included); the current diagnosis may be the patient’s first diagnosis of melanoma or recurrent melanoma after previous diagnosis of an earlier stage melanomaXx_NEWLINE_xXParticipants who have been diagnosed with clinical or pathologic stage IB to stage IIIA adenocarcinoma of the breast (any subtype) who have undergone, and recovered from primary therapy (any combination of surgery, radiation, and/or chemotherapy and/or trastuzumab used to treat newly diagnosed disease), with their last dose/treatment (of any single or combination treatment) being between 45 days and 6 months (180 days) prior to enrollment; staging will be based on the Seventh Edition American Joint Committee on Cancer (AJCC) staging system; (systemic staging with computed tomography [CT] or positron emission tomography [PET] scans is not required by AJCC and is not required nor exclusionary for this trial)Xx_NEWLINE_xXPatients must have Durie-Salmon stage II or III diseaseXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) clinical stage I with T1 > 1.5 cm, stage II or III invasive breast cancer; participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study and no tumor is HER2-positive; in this circumstance, the investigator must determine which will represent the target lesion to be assessed for response; this should remain consistent throughout the study; the target lesion should be selected on the basis of its size (lesion with the longest diameter) and suitability for accurate repetitive measurementsXx_NEWLINE_xXHistologic or cytologic diagnosis of cutaneous melanoma, mucosal melanoma, or melanoma of unknown primary that is considered unresectable (stage III) or metastatic (stage IV)Xx_NEWLINE_xXChronic kidney disease > stage 3.Xx_NEWLINE_xXT stage of T2 with the tumor > 3 cm in maximum diameter or a T stage >= 3Xx_NEWLINE_xXPatients must have primary cutaneous melanoma that belong to one of the following American Joint Commission on Cancer (AJCC) stages (2009 AJCC Melanoma Staging System):\r\n* Stage IIIB\r\n** T1-4b N1a M0\r\n** T1-4b N2a M0\r\n** T1-4b N1b M0\r\n** T1-4b N2b M0\r\n** T1-4b N2c M0\r\n* Stage IIIC\r\n** T1-4b N1b M0\r\n** T1-4b N2b M0\r\n** T1-4b N2c M0\r\n** Any T N3 M0\r\n* Stage IV \r\n** M1a\r\n** M1b\r\n** NOTE: patients with stage IV melanoma must have normal lactate dehydrogenase (LDH) and either distant skin, subcutaneous, lymph node, or lung metastases, but no other visceral metastases in order to be eligible; for patients with resected stage IV melanoma, LDH within the institutional upper limit of normal (ULN) must be documented within 4 weeks prior to randomizationXx_NEWLINE_xXPatients with stage IV (locally advanced or metastatic) disease; the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition will be used for staging; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria will be used for measurable diseaseXx_NEWLINE_xXPatients with newly diagnosed, histologically confirmed Hodgkin lymphoma (HD) who meet the following criteria:\r\n* Stage IA and IB (excluding non-bulky nodular lymphocyte predominant)\r\n* Stage IIA and IIB\r\n* Stage IIIA\r\n* Stage IVAXx_NEWLINE_xXPatients with stage IIIB (not eligible for definitive chemo-radiotherapy), stage IV, or recurrent non-small cell lung cancer (NSCLC); patients with stage IV NSCLC should have previously received platinum based doublet chemotherapy; patients with a new diagnosis of stage IV NSCLC are eligible if they have an initial requirement for palliative (radiation therapy) XRT for symptomatic lesion (example: painful bone lesion or obstructive airway)Xx_NEWLINE_xXHER-2 negative breast cancer that at the time of study entry is either stage III (locally advanced) disease not amenable to curative therapy or stage IV disease; histological confirmation of recurrent/metastatic disease is encouraged but not required if clinical evidence of stage IV disease is availableXx_NEWLINE_xXBreast cancer patients with stage 0, stage I, stage IIAXx_NEWLINE_xXStage 2 endometrial and ovarian cancer patients must have at least one lesion amenable to biopsy; this determination will be made by a member of the interventional radiology team or surgical associate investigator and an associate investigator; this requirement is not necessary for patients in stage 1Xx_NEWLINE_xXClinical stage III or IVXx_NEWLINE_xXPathologically or cytologically documented stage IIIB/IV non-small cell lung cancer, or unresectable recurrent disease following locoregional treatmentXx_NEWLINE_xXPatients must have histological or cytological confirmed melanoma that is metastatic or that is unresectable stage III and clearly progressiveXx_NEWLINE_xXHave histologically proven diagnosis of non-small cell lung cancer (NSCLC) (stage III and stage IV [to include limited volume metastases such as brain, bone, adrenal])Xx_NEWLINE_xXStage III or stage IVA or IVB disease prior to induction chemotherapy with no proven hematogenous metastatic diseaseXx_NEWLINE_xXPatients with metastatic disease (only stage III or IVA-B patients permitted)Xx_NEWLINE_xXPatients must have low- or intermediate-risk adenocarcinoma of the prostate as defined by:\r\n* Low-risk disease\r\n** Histopathology score (Gleason sum): =< 6, and T-stage (per current American Joint Committee on Cancer [AJCC] staging criteria): T1c-T2a, and prostate-specific antigen (PSA) < 10\r\n* Intermediate-risk disease as either:\r\n** Histopathology score (Gleason sum): =< 6, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA: > 10 but =< 20 Or\r\n** Histopathology score (Gleason sum): 7 with =< 50% cores positive, T-stage (per current AJCC staging criteria): T1c-T2a, and PSA < 10Xx_NEWLINE_xXClinical stage Tx, T1-T4, N1-3, M0Xx_NEWLINE_xXPatients who are treatment naïve, high risk, stage IVa/IVb (all other sites) and histologically proven squamous cell carcinoma of the head and neck (SCCHN) with no definitive evidence of metastatic disease, excluding patients with oropharynx human papillomavirus (HPV)-positive tumors; in summary, those patients eligible are newly diagnosed and treatment naive: \r\n* Stage IVa-b squamous cell carcinoma other than oropharyngeal cancer (OPC), or\r\n* Oropharyngeal cancer (OPC) HPV-negative, stage IVa-bXx_NEWLINE_xXPatients who are treatment naïve, high risk, stage IVa/IVb (all other sites) histologically proven SCCHN with no definitive evidence of metastatic disease; in summary, those patients eligible are:\r\n* Stage IVa-b SCCHN other than OPC, or\r\n* OPC, HPV-negative, IVa-b, or\r\n* OPC, HPV positive, with greater than 10 pack-year smoking history and N2b-N3 diseaseXx_NEWLINE_xXPatients must have unresectable stage III or stage IV melanoma, either initial presentation or recurrent, that is of cutaneous origin or unknown primary origin and that is histologically diagnosedXx_NEWLINE_xXPatients must have unresectable metastatic stage IV melanoma or stage III intransit or regional nodal disease, and in the opinion of the institutional Principal Investigator (PI) is an acceptable candidate for ACT with high dose IL-2 (aldesleukin)Xx_NEWLINE_xXPatients must have pathologically-confirmed, previously untreated, stage III-IV (excluding N3 or T4) squamous cell carcinoma of the oropharynx, without evidence of distant metastasisXx_NEWLINE_xXPatients must have unresectable metastatic stage IV melanoma or stage III in-transit or regional nodal disease and in the opinion of the principal investigator (PI) or treating co-investigator is an acceptable candidate for ACTXx_NEWLINE_xXSubjects must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 E or K mutation determined by pyrosequencing assay or Food and Drug Administration (FDA)-approved equivalent test, meeting one of the following American Joint Committee on Cancer (AJCC) staging criteria: \r\n* AJCC stage IV (Tany, Nany, M1a, b, or c) \r\n* AJCC stage III B or C with unresectable nodal/locoregional involvementXx_NEWLINE_xXPatients must have histologically or cytologically confirmed:\r\n* Extensive stage small cell lung cancer (SCLC) or \r\n* Stage IV (M1a or M1b according to American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition) large cell neuroendocrine non-small cell lung cancer (NSCLC) or \r\n* Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy \r\n** NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathyXx_NEWLINE_xXPHASE II: Patients must have extensive stage, histologically or cytologically confirmed small cell lung cancer; NOTE: the extensive disease classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathyXx_NEWLINE_xXPatients must be clinical American Joint Committee on Cancer (AJCC) stage IIIA or IIIB (AJCC, 7th ed.) with non-operable disease; non-operable disease will be determined by a multi-disciplinary treatment team, involving evaluation by at least 1 thoracic surgeon within 8 weeks prior to registration; Note: For patients who are clearly nonresectable, the case can be determined by the treating radiation oncologist and a medical oncologist, or pulmonologistXx_NEWLINE_xXClinical stage Tis or T1mi N0 M0Xx_NEWLINE_xXPhase I: Patients must have histologically confirmed breast cancer (metastatic breast cancer [MBC]) that is human epidermal growth factor receptor 2 (HER2/neu) negative (as determined by local pathology or reference laboratory), and have disease that is metastatic (stage IV [TxNxM1]) or locally advanced and not amenable to potentially curative surgical resection (eg, clinical stage IIIB-C)Xx_NEWLINE_xXHistologic diagnosis of unresectable stage III or IV melanoma\r\n* All melanomas regardless of primary site of disease will be allowedXx_NEWLINE_xXPathologically proven diagnosis of stage IIIA (T1-T3) (American Joint Committee on Cancer [AJCC] Staging, 7th edition) with a single primary lung parenchymal lesion and ipsilateral positive mediastinal nodes within 12 weeks of registration; note: the primary tumor does not require tissue diagnosis; documentation of non-small cell carcinoma may originate from the mediastinal node biopsy or aspirationXx_NEWLINE_xXFor advanced (stage III/IV) Hodgkin's disease, patients must have failed an adriamycin containing regimen (ABVD) or an alternative non-cross resistant regimen (e.g. MOPP)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXCompletely surgically resected stage IIIb/c/d or stage IV melanoma within 12 weeks of participation in study.Xx_NEWLINE_xXPatients must have advanced (stage III-IV) or recurrent histologically confirmed USPCXx_NEWLINE_xXLocally confirmed dMMR or MSI-H stage IV colorectal carcinomaXx_NEWLINE_xXHistologically confirmed MBC, current stage IV.Xx_NEWLINE_xXHas Barcelona Clinic Liver Cancer (BCLC) Stage C disease, or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approach.Xx_NEWLINE_xXAll Stage IV patients are eligible, irrespective of residual disease, after primary or interval debulking. Stage III patients are required to have visible residual disease after primary surgery. Patients with inoperable Stage III and IV disease are eligibleXx_NEWLINE_xXComplete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by the American Joint Committee on Cancer (AJCC) 7th Edition staging criteriaXx_NEWLINE_xXPatients must have non-bulky stage I or II disease by Ann Arbor classification\r\n* This staging excludes fludeoxyglucose F 18 (FDG)-PET evaluation\r\n* Patients who have stage I or II non-bulky disease based on diagnostic CT scan, but are upstaged to stage III or IV based on FDG-PET evaluation, are also eligible\r\n* Stage and bulk are assigned using measurements obtained prior to biopsyXx_NEWLINE_xXDiagnosed with stage IV Non-Small Cell Lung CancerXx_NEWLINE_xXDiagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.Xx_NEWLINE_xXSubjects with FIGO Stage Ic, Stage II, Stage III, Stage IV, recurrent, or persistent (unresectable) histologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube carcinoma.Xx_NEWLINE_xXBarcelona Clinic Liver Cancer (BCLC) Stage C disease (Llovet et al 1999), or BCLC Stage B disease.Xx_NEWLINE_xXFIGO 2008 stage IIIA diseaseXx_NEWLINE_xXSingle organ involvement (Stage 1-3 skin, Stage 1 upper GI, or Stage 1-2 lower GI)Xx_NEWLINE_xXMultiple organ involvement (Stage 1-3 skin plus stage 1 upper GI, Stage 1-3 skin plus stage 1 lower GI, Stage 1-3 skin plus stage 1 lower GI plus stage 1 upper GI, Stage 1-3 skin plus stage 1-4 liver, or Stage 1 lower GI plus stage 1 upper GI)Xx_NEWLINE_xXHave unresectable Stage III or Stage IV melanoma, as per AJCC staging system not amenable to local therapyXx_NEWLINE_xXCentrally confirmed Stage IV/M1 mTNBCXx_NEWLINE_xXPatients must have completely resected melanoma of cutaneous origin or of unknown primary in order to be eligible for this study; patients must be classified as stage IIIA (N2a), IIIB, IIIC, or stage IV melanoma; patients with non-ulcerated T1b N1a disease are not eligible; patients with melanoma of mucosal or other non-cutaneous origin are eligible; patients with melanoma of ocular origin are not eligible; patients with a history of brain metastases are ineligibleXx_NEWLINE_xXPhysical examination indicates Tanner Stage 1Xx_NEWLINE_xXParticipants receiving alectinib in either Stage 1 or Stage 2: must be ALK positive as assessed by Food and Drug Administration (FDA) approved test and must not have received prior treatment for their advanced NSCLC.Xx_NEWLINE_xXHistologically confirmed stage 1 through stage 3c primary adenocarcinoma of the breastXx_NEWLINE_xXBreast cancer, which at the time of study entry is either stage III (locally advanced) disease not amenable to curative therapy or stage IV disease; histological confirmation of recurrent/metastatic disease is encouraged but not required if clinical evidence of stage IV disease is availableXx_NEWLINE_xXStage M1Xx_NEWLINE_xXHistologically documented squamous cell carcinoma of the oropharynx (stage III-IV A,B)Xx_NEWLINE_xXDistant metastases (stage IV C, any T, any N and M1)Xx_NEWLINE_xXStage 1: both NT-proBNP and troponin T under thresholdXx_NEWLINE_xXStage 2: either NT-proBNP or troponin T (but not both) over threshold;Xx_NEWLINE_xXNo prior systemic treatment for unresectable stage IIIB or IV NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLCXx_NEWLINE_xXMetastatic (Stage IV) or recurrent NSCLC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.Xx_NEWLINE_xXStage IV MSS CRC (according to American Joint Committee on Cancer 7th edition guidelines) who have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.Xx_NEWLINE_xXUnresectable Stage III or Stage IV melanoma, as per American Joint Committee on Cancer staging system not amenable to local therapy.Xx_NEWLINE_xXStage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer 7th edition guidelines) with documented disease progression while on a PD-1 pathway targeted therapy.Xx_NEWLINE_xXHas locally advanced/metastatic disease, i.e., newly diagnosed Stage IV RCC per American Joint Committee on Cancer (AJCC) or have recurrent disease.Xx_NEWLINE_xXClinical stage ? T2bXx_NEWLINE_xXISS Stage III; orXx_NEWLINE_xXISS stage III; orXx_NEWLINE_xXHave advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;Xx_NEWLINE_xXHistologically-confirmed (1) NSCLC, (2) bladder cancer, (3) castrate-resistant prostate cancer which are metastatic, or (4) stage 3C or stage 4 melanoma.Xx_NEWLINE_xXStage T3-4 diseaseXx_NEWLINE_xXPatients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligibleXx_NEWLINE_xXEither clinical or pathological Stage I (T1c), II, or III according to AJCC 7th editionXx_NEWLINE_xXPathologically or cytologically confirmed NSCLC Stage IV Cancer (includes cytologically proven pleural effusion or pericardial effusion) or recurrent disease. Staging is based on American Joint Committee on Cancer (AJCC) Staging for NSCLC 7th edition (R12-4710)Xx_NEWLINE_xXPatients must have histologically-confirmed stage IV TNBC (patients who had metastatic disease within 6 months of lumpectomy or mastectomy for treatment of TNBC may be excused from repeat biopsy)Xx_NEWLINE_xXUntreated or previously received one treatment regimen for measurable unresectable stage III or stage IV melanoma (American Joint Committee on Cancer [AJCC] 2010) (for BRAF wild-type, and regardless of human leukocyte antigen [HLA] type); untreated or previously received up to two treatment regimens for measurable unresectable stage III or stage IV melanoma (AJCC 2010) (for BRAF mutant, and regardless of HLA type; If 2 prior regimens, one should be a BRAF inhibitor); this does not include any therapies given in the adjuvant settingXx_NEWLINE_xXStages II bulky disease (defined as mass size of more than 10 cm), stage III, or IV (Ann Arbor staging); patients with stage I and stage II non-bulky disease are excluded from this studyXx_NEWLINE_xXStage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLCXx_NEWLINE_xXClinical Masaoka stage II (> 5 cm), III, or IVA, including suspected invasion of mediastinum, pericardium, lung, great vessels or chest wall, and/or pleural metastasesXx_NEWLINE_xXHistologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)Xx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of NSCLC with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)Xx_NEWLINE_xXHave histologically or cytologically confirmed stage IIIB (and not a candidate for definitive multimodality therapy) or stage IV NSCLC.Xx_NEWLINE_xXMale or female patients with metastatic, histologically- or cytologically-confirmed unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) of squamous histology (Staging per American Joint Committee on Cancer [AJCC], Edition 7). Mixed histology adenosquamous NSCLC will also be permitted.Xx_NEWLINE_xXThere must be histologic confirmation of high risk, adenocarcinoma of the colon defined as AJCC 7th Edition Stage IIIB or IIIC.Xx_NEWLINE_xXPrior chemotherapy for extensive-stage SCLCXx_NEWLINE_xXStage IIIb/C or Stage IV before complete resectionXx_NEWLINE_xXAnn Arbor stage II to IV.Xx_NEWLINE_xXStage IIIb/IV NSCLCXx_NEWLINE_xXPatients with selected Stage III or IV disease (T2 N2-3 M0, T3-4 any N M0, T1 N2b, N2c or N3p16 negative oropharynx cancer or T1-2 any N hypopharynx cancer) including no distant metastases.Xx_NEWLINE_xXRadiological stage T1-T2 N0 Mx/M0 disease.Xx_NEWLINE_xXStage II, III, or IV diseaseXx_NEWLINE_xXPrior treatment with immunotherapy for any stage NSCLC, including early-stage (neoadjuvant or adjuvant) diseaseXx_NEWLINE_xXSubject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that is unresectable or metastaticXx_NEWLINE_xXHas Barcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment approachXx_NEWLINE_xXPatients with initial diagnoses of stage IV diseaseXx_NEWLINE_xXNew diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer.Xx_NEWLINE_xXPathologically confirmed (histology or cytology) clinical Stage II, III, or IVA squamous cell cancer of the oral cavity (excluding lip). Subjects must be staged using AJCC Cancer Staging Manual Edition 7.0 (appendices 1 and 2).Xx_NEWLINE_xXStaging MRI must confirm American Joint Committee on Cancer (AJCC) stage T1, T2a, T2b or T2c;Xx_NEWLINE_xXConfirmed diagnosis of stage IV NSCLC.Xx_NEWLINE_xXStage IV disease diagnosed within 6 weeks of randomizationXx_NEWLINE_xXHave stage IV disease at the time of study entry (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition).Xx_NEWLINE_xXHistologically documented, locally advanced or recurrent (stage IIIB who are not eligible for combined modality treatment) or metastatic (Stage IV) NSCLCXx_NEWLINE_xXPre- or post-menopausal women with stage II-III breast cancer (American Joint Committee on Cancer [AJCC] 2002)Xx_NEWLINE_xXUnresectable Stage III or Stage IV melanoma (AJCC 2010)Xx_NEWLINE_xXPatients must have histologically confirmed advanced (FIGO Stage III or IV), persistent, or recurrent endometrial carcinoma, which is not likely to be curable by surgery or radiotherapy. Histologic documentation of the recurrence is not required.Xx_NEWLINE_xXStage T3b or greater diseaseXx_NEWLINE_xXStage IB (with a primary tumor >= 4cm), IIA, IIB, or IIIA (according to American Joint Committee on Cancer [AJCC] 7th edition); patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumorXx_NEWLINE_xXPatients must have pathologically documented breast cancer which is stage IVXx_NEWLINE_xXHave confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.Xx_NEWLINE_xXFailure, ineligible or intolerant of approved therapies; any number of prior systemic therapeutic regimens for unresectable stage III or stage IV melanoma; this includes chemotherapy, immunotherapy, pathway inhibitors, biochemotherapy, or investigational treatments; patients may also have received therapies in the adjuvant settingXx_NEWLINE_xXStage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging systemXx_NEWLINE_xXStage IV (metastatic) breast cancerXx_NEWLINE_xXPreviously untreated stage III/IV advanced or metastatic MEL (Part 1C only)Xx_NEWLINE_xXFor all Parts: The participant must have stage IV non-small cell lung cancer (NSCLC).Xx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) testXx_NEWLINE_xXParticipants with no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLCXx_NEWLINE_xXSubjects with histologically-or cytologically-documented NSCLC [squamous (SQ) or nonsquamous (NSQ)] who present with Stage IIIB/Stage IV disease (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology), or with recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for locally advanced disease)Xx_NEWLINE_xXSubjects who are ipilimumab naïve with progressive unresectable stage III or stage IV melanoma who are either treatment naïve or may have been treated with up to 3 prior treatments for melanoma (e.g. chemotherapy, biologic or targeted therapy or interleukin [IL]-2)Xx_NEWLINE_xXHistologic or cytologic confirmation of stage III or stage IV melanomaXx_NEWLINE_xXCervical carcinoma of Stage 1B or less.Xx_NEWLINE_xXPreviously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteriaXx_NEWLINE_xXPrior diagnosis of Stage IV ovarian cancer; Stage III ovarian cancer must have a 5-year disease-free interval; Stage II ovarian cancer must have a 2-year disease-free intervalXx_NEWLINE_xXPatients must be intermediate or high-risk Rai stage CLL\r\n* Intermediate risk (formerly Rai stage I/II) is defined by lymphocytosis plus enlarged lymph nodes at any site, with or without hepatomegaly or splenomegaly\r\n* High risk (formerly Rai stage III/IV) is defined by lymphocytosis with or without enlarged nodes and spleen plus disease-related anemia (hemoglobin < 11 g/dL) or thrombocytopenia (platelet count < 100 x 10^9/L) that is not attributable to autoimmune hemolytic anemia or thrombocytopeniaXx_NEWLINE_xXPatients must be HLA-A2+ and have histologically confirmed melanoma that is metastatic (stage IV) or unresectable stage IIIB/C and for which standard curative or palliative measures do not exist or are no longer effectiveXx_NEWLINE_xXStage IV melanoma or stage III melanoma that is unlikely to be cured by surgeryXx_NEWLINE_xXPatients must have adequate TIL (at least 40 x 10^6 cells at the pre-expansion stage)Xx_NEWLINE_xXSubjects categorized to stage B (not applicable for transarterial chemoembolization [TACE]) or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging systemXx_NEWLINE_xXCurrently receiving or less than 28 days since ending systemic anticancer treatment for unresected stage IIIB to IV melanomaXx_NEWLINE_xXParticipants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resectedXx_NEWLINE_xXHistologically confirmed Stage IIb, IIc, III melanomaXx_NEWLINE_xXPathologically proven diagnosis of carcinoma of the bladder within 105 days prior to registration\r\n* Operable patients whose initial tumor is a primary high grade urothelial carcinoma of the bladder exhibiting histologic evidence of invasion into the lamina propria (disease clinical stage T1) or a high grade stage Ta urothelial carcinoma without hydronephrosis; patients who have involvement of the prostatic urethra with urothelial carcinoma and have no evidence of stromal invasion of the prostate remain eligible; if the patient’s initial tumor was a high grade stage Ta urothelial carcinoma then his/her recurrent tumor must be a high grade stage T1 urothelial carcinoma to be eligibleXx_NEWLINE_xXHistologically confirmed melanoma that is considered surgically incurable with either: \r\n* Stage IIIc melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis\r\n* Stage IV melanoma (M1a, M1b, or M1c)Xx_NEWLINE_xXHigh-risk NB as defined by risk-related treatment guidelines and the International NB Staging System i.e., stage 4 with (any age) or without (> 365 days of age) v-MYC myelocytomatosis viral related oncogene, neuroblastoma derived (avian) (MYCN) amplification, MYCN-amplified stage 3 (unresectable; any age), or MYCN-amplified stage 4SXx_NEWLINE_xXHistologic diagnosis of unresectable III or stage IV metastatic melanomaXx_NEWLINE_xXNewly diagnosed stage IIIA/B NSCLC, PS 0-1Xx_NEWLINE_xXMeasurable Stage IIIA or IIIB diseaseXx_NEWLINE_xXPatients must be considered unresectable or inoperable. Patients with nodal recurrence after surgery for early-stage NSCLC are eligible if the following criteria are met:Xx_NEWLINE_xXStage III A or B disease with minimum diagnostic evaluation within 6 weeks to include:Xx_NEWLINE_xXClinical stage T2-4a; N0/X; M0Xx_NEWLINE_xXPatients enrolled in the single agent expansion stage must have a diagnosis of EOC, while patients enrolled in the combination dose escalation or expansion stage must have a diagnosis of melanoma, NSCLC, SCLC, RCC, BLC, or TNBC.Xx_NEWLINE_xXFor patients with EOC enrolled in the single agent expansion stage:Xx_NEWLINE_xXFor patients with melanoma enrolled in the combination dose escalation or expansion stage:Xx_NEWLINE_xXThe patient must have a pathologically confirmed (by histology or cytology) diagnosis of melanoma, which is currently Stage 3 (unresectable) or Stage 4 disease.Xx_NEWLINE_xXFor patients with NSCLC enrolled in the combination dose escalation or expansion stage:Xx_NEWLINE_xXThe patient must have a pathologically confirmed (by histology or cytology) diagnosis of NSCLC, which is currently Stage 3B or Stage 4 disease.Xx_NEWLINE_xXFor patients with SCLC enrolled in the combination dose escalation or expansion stage:Xx_NEWLINE_xXFor patients with RCC enrolled in the combination dose escalation or expansion stage:Xx_NEWLINE_xXFor patients with BLC enrolled in the combination dose escalation or expansion stage:Xx_NEWLINE_xXThe patient must have a pathologically confirmed diagnosis of urothelial BLC, which is currently Stage 4 disease.Xx_NEWLINE_xXFor patients with TNBC enrolled in the combination dose escalation or expansion stage:Xx_NEWLINE_xXHistologically confirmed advanced (Stage IIIB/IV) NSCLC (all histologies including squamous and sarcomatoid)Xx_NEWLINE_xXPatients must have histologically confirmed metastatic melanoma with measurable, stage III (lymph node or in transit lesions) or stage IVA, IVB, or IVC disease.Xx_NEWLINE_xXPrior chemotherapy for extensive-stage SCLCXx_NEWLINE_xXAnn Arbor stage 3 or 4 or stage 2 with bulky diseaseXx_NEWLINE_xXNaive or any number of prior systemic therapeutic regimens for unresectable stage III or stage IV melanoma, except prior BRAF or MEK inhibitor agents; this includes chemotherapy, immunotherapy, biochemotherapy, or investigational treatments; patients may also have received therapies in the adjuvant settingXx_NEWLINE_xXStage IV or recurrent pancreatic cancer by imagingXx_NEWLINE_xXFemale patients must have high risk resected stage I or 2 disease (papillary serous, clear cell, carcinosarcoma histology or grade 3), advanced stage (III or IV, all histologies) or recurrent endometrial cancer (all histologies); patients do not need measurable disease and can enroll following surgeryXx_NEWLINE_xXStage IV breast cancer, stage IV non-small cell lung cancer (NSCLC), stage IV sarcomaXx_NEWLINE_xXParticipant has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior systemic platinum based chemotherapy.Xx_NEWLINE_xXParticipant has received more than one line of therapy for stage IIIB or IV diseaseXx_NEWLINE_xXStage II, III, or IV diseaseXx_NEWLINE_xXStage III/IV disease by Ann Arbor StagingXx_NEWLINE_xXConfirmed treatment-naive de novo cluster of differentiation (CD)20 positive (+) diffuse large B cell lymphoma (DLBCL), regardless of cell of origin, with stage II-IV disease, or stage I disease if 6 cycles of chemotherapy are plannedXx_NEWLINE_xXSubject has BCLC stage B or C.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage IIIB/C or stage IV oligometastatic melanoma; oligometastatic melanoma is defined as three or fewer areas of resectable disease excluding central nervous system and bone involvement; patients with cutaneous, mucosal, acral, ocular or unknown primary melanomas are eligible for enrollment; for patients with stage IV disease with distant lymph nodes (stage M1a), a maximum of three separate lymph node sites fit the definition of oligometastatic disease; resectable tumors are defined as having no significant vascular, neural or bony involvement; only cases where a complete surgical resection with tumor-free margins can safely be achieved are defined as resectableXx_NEWLINE_xXSubjects with either limited or extensive disease stage at the initial diagnosisXx_NEWLINE_xXPatients must have histologically confirmed MCC that is Stage III (IIIB) or Stage IV, as defined by the 2010 AJCC staging criteria for MCC. MCC of unknown primary is allowed.Xx_NEWLINE_xXStage T1-2N1-2c/T3-4N0-2c disease, as defined by American Joint Committee on Cancer (AJCC) criteriaXx_NEWLINE_xXThe participant has Stage IV NSCLC.Xx_NEWLINE_xXPart A: NSCLC Stage IV (any type)Xx_NEWLINE_xXPart B: NSCLC Stage IV (squamous and nonsquamous)Xx_NEWLINE_xXPart C: NSCLC Stage IV in Japanese participants (squamous and nonsquamous)Xx_NEWLINE_xXPatients with stage III, HER2-negative cancer in the contralateral breastXx_NEWLINE_xXPatients with stage I or II, melanoma who are not candidates for ipilimumabXx_NEWLINE_xXStage II or III esophageal carcinoma according to the American Joint Committee on Cancer (AJCC) 7th edition stagingXx_NEWLINE_xXSubject with stage IIIB to IVM1c melanoma for whom surgery is not recommendedXx_NEWLINE_xXCompletely resected Stage III melanomaXx_NEWLINE_xXDocumented evidence of NSCLC (Stage IIIB/ IV disease)Xx_NEWLINE_xXMust have unresectable or inoperable stage IIIA or IIIB disease. Patients are considered unresectable or inoperable based on the judgment of the treating physicianXx_NEWLINE_xXLocally and/or regionally advanced (M0) head and neck squamous cell carcinoma (American Joint Committee on Cancer [AJCC] stage III-IVB), cytologically or pathologically confirmed by Department of Pathology at Memorial Sloan-Kettering Cancer Center (MSKCC), for which curative-intent radiation therapy is plannedXx_NEWLINE_xXHistory of histologically-confirmed stage 0, I, II, or III breast carcinoma without evidence of disease at trial entry; participants with a resected local recurrence are eligible; site study physicians will review histology from documented pathology reports (which will be recorded in the Inclusion Criteria Case Report Form [CRF]); a separate consent will be obtained for release of medical records to document history of breast cancer diagnosis, staging, and treatment (which will be captured on the Medical History CRF); participants who have a documented history in their medical record of stage 0, I, II, or III breast carcinoma without evidence of disease at trial entry are eligibleXx_NEWLINE_xXPatients must have Stage IIIB, IIIC or IV melanoma, which is unresectable/unresected or histologically confirmed diagnosis of metastatic malignant melanoma.Xx_NEWLINE_xXPatients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) T1-T4 nodal stage N2 or N3 or a T3 or T4 primary tumor with any nodal stageXx_NEWLINE_xXStage IV HER2 (+) breast cancerXx_NEWLINE_xXAdvanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV) RCCXx_NEWLINE_xXDocumented clinical stage IA, IB or IIA CTCLXx_NEWLINE_xXAll grossly visible disease in the bladder must be fully resected and pathologic stage will be confirmed at the study institutionXx_NEWLINE_xXClinical American Joint Committee on Cancer (AJCC) stage II-III (AJCC, 7th ed.) with plans to be treated with concurrent chemoradiotherapy\r\n* Recurrent non-small cell lung cancer is allowed, provided the intent of the current treatment is curative and there has been no prior radiation to the thorax\r\n* Prior chemotherapy, immunotherapy, or targeted therapy is permitted as long as patients have recovered from prior toxicities to grade =< 1Xx_NEWLINE_xXHistologic or cytologic proof of surgically unresectable stage IV malignant melanoma - including that of uveal and mucosal origin\r\n* Note: biopsy can be of locoregional disease in setting of clinically evident stage IV disease; a biopsy of the primary tumor alone does not fulfill this requirementXx_NEWLINE_xXMetastatic disease (Stage IV) or bilateral breast cancerXx_NEWLINE_xXPatients must have histologically or cytologically confirmed locally advanced head and neck cancer of squamous type stage III, IVA and IV B (larynx, oral cavity, oropharynx and hypopharynx or unknown primary isolated to the head and neck region) and select stage II tumors of the base of the tongue (BOT) (size more than 3 cm), who are appropriate for potentially curative therapy with chemoradiotherapy or surgical resection, as determined by the multidisciplinary head and neck cancer clinical care and research teamXx_NEWLINE_xXHistologically confirmed recurrent or metastatic SCCHN (oral cavity, pharynx, larynx), stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy)Xx_NEWLINE_xXPatients must be stage 0-II based on Rai staging system; must have no indication for treatment for SLL per NCI-WG criteriaXx_NEWLINE_xXDocumented evidence of NSCLC (stage IIIB/IV disease)Xx_NEWLINE_xXSubjects must have histologically-confirmed diagnosis of IDH1 gene-mutated cholangiocarcinoma Stage II, III, or IV (intra-hepatic, extra-hepatic and perihilar) that is not eligible for curative resection, transplantation, or ablative therapies. Tumors of mixed histology are not allowed.Xx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) (7th edition) stage IIb, III, or IV patients planned for resection of the primary tumor \r\n* > 5 cm in greatest dimension\r\n* Intermediate or high-grade \r\n* Superficial or deepXx_NEWLINE_xXPatients must have biopsy proven metastatic NSCLC (stage IV)Xx_NEWLINE_xXHistologically confirmed Stage IV, or Recurrent NSCLC with no prior systemic anticancer therapyXx_NEWLINE_xXParticipants must have histologically confirmed hormone receptor positive (HR+), human epidermal growth factor 2 (HER2) negative stage II or stage III invasive breast cancer; evaluation for metastatic disease is not required in the absence of symptomsXx_NEWLINE_xXLocally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLCXx_NEWLINE_xXStage III or IV cancer, other than breast cancer, in =< 5 years prior to registrationXx_NEWLINE_xXHave metastatic disease (stage IV) confirmed surgically, by imaging or pathologicallyXx_NEWLINE_xXStage Tis, T1, or T2 laryngeal squamous cancer as defined by American Joint Commission on Cancer (AJCC) 2007 staging systemXx_NEWLINE_xXDirect laryngoscopy showing no evidence of greater than stage II true glottic larynx cancerXx_NEWLINE_xXEvidence of thyroid or soft tissue invasion (stage cT4)Xx_NEWLINE_xXEvidence of positive nodal disease (stage N1)Xx_NEWLINE_xXCancer should be staged via American Joint Committee on Cancer (AJCC) as stage II, III, IVa, or IVbXx_NEWLINE_xXMemorial Sloan Kettering Cancer Center (MSKCC) pathologically-proven diagnosis of locally advanced stage III not amenable to definitive, curative treatment or stage IV or recurrent non-small cell lung cancerXx_NEWLINE_xXClinical stage T1N0M0 (by American Joint Committee on Cancer [AJCC] 2010 criteria)\r\n* Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or micronodular features must be =< 1 cmXx_NEWLINE_xXFIGO stage IA1, IB2, II, III or IV diseaseXx_NEWLINE_xXStage III/IV disease (stage II is also eligible if disease is not encompassible within a single radiation field)Xx_NEWLINE_xXHistologically confirmed metastatic breast cancer (MBC), current stage IVXx_NEWLINE_xXHas a histologically-confirmed, unresectable or metastatic (Stage IV American Joint Committee on Cancer [AJCC seventh edition]) colorectal cancer (CRC)Xx_NEWLINE_xXMust not have received prior systemic chemotherapy for Stage IV CRCXx_NEWLINE_xXWith histologically or cytologically confirmed recurrent or refractory unresectable Stage IV gastric or gastro-esophageal junctional adenocarcinoma (according to American Joint Committee on Cancer/Union Internationale Contre le Cancer [UICC] 7th edition) and whose disease progressed after one or two prior chemotherapy regimen(s) involving both fluoropyrimidines and platinumXx_NEWLINE_xXPART A: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the American Joint Committee on Cancer [AJCC] staging manual)Xx_NEWLINE_xXPART B: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the AJCC staging manual)Xx_NEWLINE_xXPatients with stage IV HER2+ breast cancer treated to:\r\n* No evidence of disease (NED), or \r\n* Stable bone only disease after definitive therapyXx_NEWLINE_xXAnn Arbor stage IIB, IIIB, IVA, or IVBXx_NEWLINE_xXDiagnosis of locally advanced, unresectable or metastatic cutaneous melanoma or unknown primary melanoma (AJCC Stage IIIB, IIIC, or IV)Xx_NEWLINE_xXPatients must have locally advanced unresectable stage IIIC or metastatic stage IV cancer with either progression to prior therapy or a newly diagnosed cancer that does not have an available treatment with curative intentXx_NEWLINE_xXPatients must have histologically confirmed melanoma with BRAF^V600 mutation; patients must have stage IIIC or stage IV diseaseXx_NEWLINE_xXPatients who are categorized under Barcelona-Cl?nic Liver Cancer (BCLC)-C stageXx_NEWLINE_xXPatients must have histologically confirmed diagnosis of stage IV metastatic melanoma positive for BRAF V600E mutation by either the COBAS test or other Clinical Laboratory Improvement Amendments (CLIA) approved assayXx_NEWLINE_xXStage II (not candidates for local x-ray therapy), III, or IV disease by the Ann Arbor ClassificationXx_NEWLINE_xXStage III patients must have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery.Xx_NEWLINE_xXPatients with early stage disease (FIGO Stage I, IIA, IIB or IIC)Xx_NEWLINE_xXPatients with synchronous primary endometrial cancer unless both of the following criteria are met: 1) stage <2 2) less than 60 years old at the time of diagnosis of endometrial cancer with stage IA or IB grade 1 or 2, or stage IA grade 3 endometrioid adenocarcinoma OR ? 60 years old at the time of diagnosis of endometrial cancer with Stage IA grade 1 or 2 endometrioid adenocarcinoma. Patients with serous or clear cell adenocarcinoma or carcinosarcoma of the endometrium are not eligible.Xx_NEWLINE_xXHistologically confirmed stage III (unresectable) or stage IV melanomaXx_NEWLINE_xXStage IV disease by AJCC criteria (7th edition).Xx_NEWLINE_xXPatients with histologically documented diagnosis of advanced stage IV or unresectable stage III mucosal or cutaneous melanoma are eligibleXx_NEWLINE_xXClinical stage IB (>= 4 cm per computed tomography [CT]), stage IIA/IIB, or stage III (N0-2) amenable to surgical resectionXx_NEWLINE_xXClinical stage IIA (T2N0), IIB (T2N1, T3N0) or stage IIIA (T1N2, T2N2, T3N1, T3N2), IIIB, or IIIC breast cancer with no prior treatmentXx_NEWLINE_xXPatients must be without visceral or bone involvement with metastatic breast cancer on physical exam or any diagnostic study; patients with extensive nodal involvement classified as stage IV disease, are eligibleXx_NEWLINE_xXPARTS A AND B: Patients with Hodgkin lymphoma (HL) are eligible for both the phase 1 and 2 portions, if they are in one of the following categories:\r\n* Primary refractory disease (i.e. no prior CR) \r\n* Very early relapse (< 6 months from the end of initial therapy, including chemotherapy ± radiation)\r\n* Advanced stage (III or IV) at diagnosis who relapse less than one year from the end of initial therapy\r\n* Note that patients with low-stage disease (IA or IIA) at initial diagnosis, who were treated with radiation alone or fewer than four cycles of chemotherapy will NOT be eligibleXx_NEWLINE_xXBarcelona Clinic Liver Cancer (BCLC) stage C, and those with BCLC-B stage who cannot tolerate or failed transarterial chemoembolization (TACE)Xx_NEWLINE_xXStage IIIB (AJCC Stage IIIB - Any T,N3M0 or T4N2M0) or Metastatic (AJCC Stage IV- any T, any N, M1), progressive, recurrent or refractory NSCLC. Patients may not be eligible for other curative intent treatment (e.g., surgical resection). For the purpose of eligibility for this trial, the above-cited disease states are defined as follows:Xx_NEWLINE_xXClinical stage T1-4/N0-3/M0 at presentation (patients with T1a/bN0 tumors will not be eligible)Xx_NEWLINE_xXStage IV (metastatic) breast cancerXx_NEWLINE_xXMetastatic (stage IV) disease (including involvement of the colon, adrenals, or kidney, or radiographic evidence of peritoneal seeding or pulmonary metastases)Xx_NEWLINE_xXDiagnosis of locally advanced, unresectable or metastatic cutaneous or melanoma of unknown primary AJCC Stage IIIC or IV (uveal and mucosal melanoma are excluded)Xx_NEWLINE_xXStage II or III disease by the American Joint Committee on Cancer (AJCC) 7th editionXx_NEWLINE_xXPatients must have stage IV breast cancerXx_NEWLINE_xXStage IB, II-A, II-B, III and IVXx_NEWLINE_xXUnresectable stage III/IV melanomaXx_NEWLINE_xXSTEP 1 ENROLLMENT: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th Edition stage IV NSCLCXx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th edition stage IV NSCLCXx_NEWLINE_xXHistologically confirmed Stage III (unresectable)/Stage IV melanomaXx_NEWLINE_xXStage 3 or 4 disease without evidence of distant metastasesXx_NEWLINE_xXInternational Association for the Study of Lung Cancer (IASLC) version 7, stage IV disease; or recurrence after prior surgery or radiotherapyXx_NEWLINE_xXPatient's disease must be pathological N-stage positiveXx_NEWLINE_xXPatient must not have pathologically N stage negative diseaseXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC [2009]) stage IIIC cutaneous melanoma rendered free of disease by surgical resection no greater than 90 days prior study enrollment; patients with unknown primaries will be eligible for this trial; patients with a history of resected stage I or II cutaneous melanoma who subsequently have their first disease recurrence meeting the criteria for stage IIIC disease will also be eligible for this trialXx_NEWLINE_xXPatients with a history of stage III melanoma (any primary melanoma with locoregional nodal/subcutaneous disease) treated with surgical resection who subsequently have disease recurrence meeting the criteria for stage IIIC diseaseXx_NEWLINE_xXCompletely resected histologically confirmed high-risk [Stage IIIa (LN metastasis more than 1 mm), IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.Xx_NEWLINE_xXHave stage IA, IB or IIA: T1 or T2 (patches or plaques) with measurable lesionsXx_NEWLINE_xXStage IIB or greater CTCLXx_NEWLINE_xXAdvanced stage NSCLC (stage IVa [malignant pleural effusion (is now staged as stage IVa by the most recent staging system), or stage IV, or recurrent disease])Xx_NEWLINE_xXBiopsy-proven invasive adenocarcinoma of the rectum, stage T3-4 and/or node-positive (American Joint Committee on Cancer [AJCC] stage II or III) per AJCC staging manual, 7th edition; patients with M1a rectal cancer (“metastasis confined to one organ or site [e.g., liver, lung, ovary, non regional node]\), stage IVA disease per the AJCC staging manual, 7th edition, are also eligible; for the purpose of this study, a tumor is located in the “rectum” when its distal edge is located =< 12cm from the anal verge; the distal edge of the tumor can be delineated by digital examination or endoscopic examination, including colonoscopy, although rigid proctoscopy is preferredXx_NEWLINE_xXPatients with recurrent, inoperable stage III, IV, M1a, b or c melanoma (any tumor thickness and any number of lymph node involvement, and in-transit metastases, or distant metastases) (American Joint Committee on Cancer [AJCC]); previously treated with any form of therapy (including chemotherapy, radiation therapy, immunotherapy or surgery) for either metastatic, relapsed, or primary melanoma are eligible for this trial, provided the previous treatment was completed > 30 days prior to enrollmentXx_NEWLINE_xXStage IIIc or Stage IV BRAF V600E/K cutaneous melanomaXx_NEWLINE_xXHistologically or cytologically proven B-cell malignancies; either Burkitt leukemia or B-AL (= Burkitt leukemia = L3-AL), or diffuse large B-cell NHL, or aggressive mature B-cell NHL non otherwise specified or specifiable (phase III)\r\n* Stage III with elevated LDH level (B-high) (LDH > twice the institutional upper limit of the adult normal values [> Nx2]), any stage IV, or B-AL (phase III)Xx_NEWLINE_xXClinical stage T2-T4a N0/X M0 diseaseXx_NEWLINE_xXHistological diagnosis:\r\n* Histologically proven diagnosis of testicular seminoma\r\n** Histologically confirmed seminomatous germ cell tumor of the testis categorized as either \classical\ or \anaplastic”\r\n* Stage I disease\r\n** Any pT N0 M0 S0-3 (American Joint Committee on Cancer [AJCC], 7th Ed.)\r\n* Stage IIA or IIB disease\r\n** Any pT N1 M0 S0-3 (AJCC, 7th Ed.)\r\n** Any pT N2 M0 S0-3 (AJCC, 7th Ed.)\r\n** (At the discretion of the principal investigators, bulky stage IIB may be excluded from the study, according to National Comprehensive Cancer Center Guidelines)Xx_NEWLINE_xXStage IV disease according to the 7th Edition of the American Joint Committee on Cancer staging systemXx_NEWLINE_xXExtent of disease: stage I - IV; patients with nodular histology mantle cell lymphoma must have Ann Arbor stage III or IV disease to be eligible\r\n* Patients with mantle zone type histology will not be eligible\r\n* Patients with other mantle cell histologies are eligible regardless of stageXx_NEWLINE_xXStage III with elevated LDH level (\B-high\), [LDH > twice the institutional upper limit of the adult normal values (> Nx2)] or any stage IV or B-AL.Xx_NEWLINE_xXPreviously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteriaXx_NEWLINE_xXPatients are eligible if they have stage III or IV disease; patients with stage 0, I or II disease will be eligible if they have evidence of active disease defined as one or more of the following signs/symptoms:\r\n* Documented weight loss of >= 10% over a six month period \r\n* Febrile episodes of 38 degrees Celsius (100.5 degrees F) or greater for greater than 2 weeks without evidence of infection \r\n* Massive or progressive splenomegaly defined as > 6 cm below the left costal margin \r\n* Massive (> 10 cm in longest diameter) or progressive lymphadenopathyXx_NEWLINE_xXAt least three years since colectomy with IRA/proctocolectomy with pouch, and demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 Staging System (Appendix B) and summarized as follows: Stage 1: 10-25 polyps, all < 5 mm Stage 2: 10-25 polyps, at least one > 1 cm Stage 3: >25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high grade dysplasia, even if completely removed. [Note: For staging purposes only.]Xx_NEWLINE_xXIntra-abdominal desmoid disease, stage III or IVXx_NEWLINE_xXModerate to end-stage kidney disease and a history of severe asthma or allergiesXx_NEWLINE_xXHistologically confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IVXx_NEWLINE_xXStage II, III, and IV disease by Ann Arbor classificationXx_NEWLINE_xXHistologic or cytologic diagnosis of pancreas adenocarcinoma advanced or recurrent (stage III or IV) that is unresectable; histologic or cytologic pathology from any prior surgery is sufficient for diagnosisXx_NEWLINE_xXPathologically confirmed diagnosis of Stage IIIB / IV adenocarcinoma of the lung.Xx_NEWLINE_xXNewly diagnosed and confirmed Stage IIIB/IV NSCLCXx_NEWLINE_xXHistologically confirmed stage IV melanoma including brain metastasisXx_NEWLINE_xXHistologically or cytologically confirmed soft-tissue sarcoma, excluding alveolar and embryonal rhabdomyosarcoma, well- and dedifferentiated adipocytic sarcomas, Ewing’s, osteosarcoma, or gastrointestinal stromal tumor; American Joint Committee on Cancer (AJCC) (6th Edition) Stage III or T2a Stage II or Stage IV treatment naive patients planned for resection of the primary tumor, with resectable metastatic diseaseXx_NEWLINE_xXAny patient eligible for internal implantation without MR guidance will be considered eligible for this protocol; standard criteria for internal implantation include:\r\n* Carcinoma of the cervix: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the uterus: stage IIIB (vaginal involvement), inoperable, or vaginal recurrence\r\n* Carcinoma of the vagina: stage I-IVA or vaginal recurrence\r\n* Carcinoma of the vulva: stage I-IVA or recurrence\r\n* Carcinoma of the urethra/bladderXx_NEWLINE_xXWomen with stage IA or IB1 cancerXx_NEWLINE_xXClinical stage 2 or greater with localized diseaseXx_NEWLINE_xXHistologically or cytologically confirmed non-small cell cancer of the lung (NSCLC) stage IV (accordingto AJCC Staging 7th Edition);Xx_NEWLINE_xXStage III or IV disease, or Stage II bulky disease (defined as tumor diameter greater than or equal to [>/=] 7 centimeters [cm])Xx_NEWLINE_xXAnn Arbor Stage I diseaseXx_NEWLINE_xXHistologic/cytologic proof of stage IV malignant melanoma not amenable to surgeryXx_NEWLINE_xXStage IV breast cancer.Xx_NEWLINE_xXStage 4 gastrointestinal GVHD as per Seattle-Glucksberg criteriaXx_NEWLINE_xXStage IV diseaseXx_NEWLINE_xXPatients with American Joint Committee on Cancer (6th edition, 2002) stage IV cancer with distant metastasesXx_NEWLINE_xXPatients with American Joint Committee on Cancer (AJCC) seventh edition stage 4 metastatic non-small cell lung carcinomaXx_NEWLINE_xXPatients may have active mediastinal disease in N2 nodal stations if he/she has not received prior mediastinal RT\r\n* No restriction on prior T or N stage for patients who develop M1 disease at some point after initial diagnosis of stage I-III lung cancer and treatmentXx_NEWLINE_xXDose-Escalation Stage:Xx_NEWLINE_xXExpansion Stage:Xx_NEWLINE_xXStage IV (M1), Stage IA, and lymph node negative breast cancer.Xx_NEWLINE_xXAny evidence of nodal positivity beyond pathologic stage of pN0(i+)Xx_NEWLINE_xXPathologic evidence of advanced stage IV or recurrent lung adenocarcinoma reviewed at Memorial Sloan Kettering Cancer Center (MSKCC)Xx_NEWLINE_xXHas extensive-stage disease defined as Stage IV (T any, N any, M 1a/b) by the American Joint Committee on Cancer (AJCC), Seventh EditionXx_NEWLINE_xXFor Melanoma Subjects: Have histologically or cytologically confirmed diagnosis of unresectable Stage III or metastatic (Stage IV) melanoma not amenable to local therapy, and irrespective of PD-L1 statusXx_NEWLINE_xXHistologically confirmed diagnosis of follicular lymphoma CD20+ (Grade 1, 2 or 3a) Ann Arbor Stage II, III or IV disease.Xx_NEWLINE_xXConfirmed stage IV or recurrent EGFR Mutation (MT)+ NSCLC with disease progression after 1 prior EGFR TKI therapyXx_NEWLINE_xXStage IV disease, confirmed by biopsy or unequivocal radiographic evidence (note: staging scans are not required, but should be performed at treating physician discretion in accordance with standard guidelines)Xx_NEWLINE_xXPatient must be American Joint Committee on Cancer (AJCC) stage III (T3N0, T1-2N1) or stage IVa (T1-4N2-3M0, T4N0-1 M0) or stage IVb (unresectable disease) and be either unresectable or borderline resectableXx_NEWLINE_xXPatients with Rai stage III-IV - OR - Patients with Rai stage 0-IIXx_NEWLINE_xXPatients with histologically documented metastatic melanoma with:\r\n* (Metastatic disease cohort) measurable disease, stage IIIB, IIIC (in transit lesions with or without nodal metastases) that includes lesions accessible for biopsies or IV M1B\r\n* (Adjuvant cohort) subjects who are no evidence of disease (NED) and stage III or IV; this includes patients with stage IV disease resected to NED; stage IIB or IIC patients will be enrolled after review and approval by the PIXx_NEWLINE_xXStage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.Xx_NEWLINE_xXStage IIIB, IIIC, or IV erbB2 (HER2) positive breast cancerXx_NEWLINE_xXAll patients with untreated Rai stage III-IV are eligible for this protocol; prior treatment with single-agent rituximab permitted; OR patients with untreated Rai stage 0-II who meet one or more criteria for active disease as defined by the International Working Group for CLL (IWCLL); prior treatment with single-agent rituximab permittedXx_NEWLINE_xXPatients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage IA2, or stage IB1 diseaseXx_NEWLINE_xXFIGO stage II-IV;Xx_NEWLINE_xXPathologic diagnosis of breast cancer and current stage IIIB, IIIC, or IVXx_NEWLINE_xXStage IIIB or Stage IV NSCLC who are not candidates for multimodality treatment and have received at least 1 line of standard platinum-based therapy:Xx_NEWLINE_xXHas a diagnosis of Stage IV rectal or rectosigmoid cancer with any multifocal metastases or single site metastasis with tumor size of > 2 cm (Intraoperative incidental finding or preoperative suspicion of Stage IV cancer with isolated (single site) metastasis (? 2 cm) or limited metastases (?3), with largest lesion ? 2 cm in size, does not exclude the subject).Xx_NEWLINE_xXAnother previous or current invasive malignancy within the last 2 years, with the exception of curatively treated stage Ia cervical carcinoma, or resected stage Ia endometrial cancer, and noninvasive nonmelanoma skin cancersXx_NEWLINE_xXPatient must have histologically or cytologically confirmed diagnosis of stage III melanoma inoperable/not amenable to local treatment or stage IV melanoma.Xx_NEWLINE_xXHistological or pathologically confirmed stage IV adenocarcinoma of the colon.Xx_NEWLINE_xXSubject has unresectable stage B (intermediate), or C (advanced) Hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging.Stage B subjects must have progressed after, or are not eligible for curative resection, transplantation, embolic, or ablative therapiesXx_NEWLINE_xXHistologically confirmed, AJCC stage II or III breast cancerXx_NEWLINE_xXStage IB-IIIAXx_NEWLINE_xXLimited stage SCLC appropriate for definitive treatment with chemoradiationXx_NEWLINE_xXStage T1-4, N0-3, M0Xx_NEWLINE_xXStage II, III or IV cardiac failureXx_NEWLINE_xXHistologically confirmed squamous advanced NSCLC (Stage IV).Xx_NEWLINE_xXHistological diagnosis of unresectable American Joint Committee on Cancer (AJCC) stage III or stage IV, v-raf murine sarcoma viral oncogene homolog B1 V600E/K mutation (BRAFV600E/K) mutant melanoma by a Clinical Laboratory Improvement Assessment (CLIA) approved testXx_NEWLINE_xXUnresectable Stage III or IV diseaseXx_NEWLINE_xXHas locally advanced or metastatic disease (Stage IIIb or Stage IV) with radiographically or clinically evaluable lesions.Xx_NEWLINE_xXParticipants must have received 1 prior platinum-based chemotherapy regimen (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb or Stage IV) disease followed by documented progressive disease (PD).Xx_NEWLINE_xXThe patient must have clinical stage T1-4, N0-3, M0-1, stage II-IVC carcinoma as per the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual; patients with T1N0M0 will be ineligible; patients with metastatic disease with a limited metastatic burden are eligible if obtaining local control is determined by their treating oncologist to be an important therapeutic goalXx_NEWLINE_xXPatients with T1N0M0 stage I diseaseXx_NEWLINE_xXHistological or cytological diagnosis of squamous cell carcinoma (SCC) of head and neck with American Joint Committee on Cancer (AJCC) Stage III, IVA or IVB and not amenable to surgical resection or locoregional radiation therapy with curative intent.Xx_NEWLINE_xXDisease may be stage I, II, III or IVA (as long as it is deemed resectable by the surgical team)Xx_NEWLINE_xXInclusion Criteria\n\n          -  Histologically and/or cytologically confirmed primary diagnosis of Stage IV NSCLC\n             (according to American Joint Committee on Cancer [AJCC] 7th edition lung cancer\n             staging criteria).\n\n          -  Measurable disease according to RECIST v.1.1.\n\n          -  An EGFR exon 19 deletion and/or an exon 21 (L858R) substitution mutation.\n\n          -  BDX004 Positive Label.\n\n          -  Have received no prior systemic chemotherapy, immunotherapy, targeted therapy, or\n             biologic therapy for metastatic NSCLC. Subjects may have previously been treated with\n             postoperative adjuvant chemotherapy for early stage lung cancer or chemo radiotherapy\n             for locally advanced disease provided this was completed at least 6 months prior to\n             enrollment. No prior EGFR TKI therapy is allowed for any stage of NSCLC.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion\n             Criteria\n\n          -  History of severe allergic or anaphylactic reactions or hypersensitivity to\n             recombinant proteins or excipients in the investigational agent or erlotinib.\n\n          -  History of known brain metastases.\n\n          -  Prior treatment with any other investigational drug or biologic agent within 5 half\n             lives prior to randomization, or any investigational device within 2 weeks prior to\n             randomization.\n\n          -  Any unresolved toxicity from previous radiation therapy.\n\n          -  Significant cardiovascular disease, including:\n\n               -  Echocardiogram (ECHO) or multiple gated acquisition (MUGA) showing left\n                  ventricular ejection fraction of less than 55%.\n\n               -  Cardiac failure New York Heart Association class III or IV.\n\n               -  Myocardial infarction, severe or unstable angina within 6 months prior to\n                  randomization.\n\n               -  History of serious ventricular arrhythmia (ie, ventricular tachycardia or\n                  ventricular fibrillation).\n\n               -  Significant thrombotic or embolic events within 3 months prior to randomization\n                  (significant thrombotic or embolic events include but are not limited to stroke\n                  or transient ischemic attack).\n\n               -  Any uncontrolled or severe cardiovascular disease.\n\n          -  History of prior malignancy within 3 years prior to randomization (except for\n             adequately treated non-melanoma skin cancer, carcinoma in situ of the breast or\n             cervix, superficial bladder cancer, or early stage prostate cancer, without evidence\n             of recurrence).\n\n          -  Radiographic evidence of interstitial lung disease.Xx_NEWLINE_xXPatients with FDG-avid and pathologically proven stage IIA-IIB or IIIA-IIIB non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)Xx_NEWLINE_xXPatients with stage I or stage IV disease, including malignant pleural or pericardial effusionXx_NEWLINE_xXPatients selected for this study will have clinical stage I or II NSCLC; subjects with evidence of enlarged N2 nodes by routine computed tomography (CT) scan imaging or those with clinical stage III or IV NSCLC are excludedXx_NEWLINE_xXPatients with operable, T2-4, N0-3, M0, T1N1 breast cancer (stage IIA, IIB, IIIA, IIIB and IIIC) with minimum tumor size of 2 cmXx_NEWLINE_xXFor Phase II: Histological diagnosis of BRAF V600E/K melanoma, unresectable stage III or stage IV, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2011; must have measurable disease, and no prior systemic treatment for locally advanced or metastatic melanoma; previous local therapy is allowed; previous systemic treatment for any stage III disease that was subsequently rendered NED (no evidence of disease) by surgery is allowed except for ipilimumab and BRAF inhibitors; patients with resectable disease who do not want surgery for any reason are also allowed; measurable disease is defined as least one lesion that can be accurately measured in two dimensions with both diameters >= 1.0 cm; for computed tomography (CT)/magnetic resonance imaging (MRI) evaluations, an effective slice thickness is required of less than or equal to 5 mm; for slice thickness greater than 5 mm, both diameters must be greater than or equal to 2.0 cm at baselineXx_NEWLINE_xXPatients with mycosis fungoides or Sezary syndrome must have stage IIb-IV disease (by International Society of Cutaneous Lymphoma [ISCL]/European Organization for Research and Treatment of Cancer [EORTC] criteria)Xx_NEWLINE_xXPatients with advanced stage NSCLC who are candidates for single or multi-agent first-line therapyXx_NEWLINE_xXMetastatic disease (Stage IV) ORXx_NEWLINE_xXPatients with cytologically or histologically confirmed non-small cell lung cancer (NSCLC) – locally advanced, stage IIIB OR stage IV or stage IVM1A (malignant pleural or pericardial effusion or pleural implants) OR recurrence after primary surgery or radiotherapy (refer to 2010 American Joint Committee on Cancer [AJCC] staging, 7th edition [Ed])Xx_NEWLINE_xXLocally advanced (Stage 3B) or metastatic (Stage 4) diseaseXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy).Xx_NEWLINE_xXHistological diagnosis of NSCLC or MPM; pts must have clinical and/or pathological evidence of pleural spread or stage III/IV MPMXx_NEWLINE_xXPts undergoing extrapleural pneumonectomy without PDT for MPM or stage IV (M1A) NSCLC (after American Joint Committee on Cancer [AJCC] staging change 2010) or stage IIIB (before staging change) with malignant pleural effusion treated at Ohio State University (OSU) from 2005-2012Xx_NEWLINE_xXHistologic or cytologic diagnosis of advanced NSCLC, Recurrent or Stage IV disease (according to American Joint Committee on Cancer (AJCC) staging system, v7.0).Xx_NEWLINE_xXHistologically-confirmed NSCLC Stage IV disease (according to the seventh edition of the lung cancer staging system)Xx_NEWLINE_xXDiagnosed with radiologically and biopsy or cytology confirmed inoperable perihilar cholangiocarcinoma Bismuth Tumor Stage III/IVXx_NEWLINE_xXHistologically confirmed diagnosis of stage IV, HER2 negative breast cancerXx_NEWLINE_xXHave a history of Stage IV Colorectal Cancer (CRC) with metastases to the liver onlyXx_NEWLINE_xXClinical stage T2-T4a, N0/x, M0 diseaseXx_NEWLINE_xXAdvanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)Xx_NEWLINE_xXPatients with histologically or cytologically documented, locally advanced (stage IIIB who are not amenable to combined modality treatment) or recurrent or metastatic (Stage IV) non-small cell lung cancer.Xx_NEWLINE_xXPatient must have measurable stage IV disease (includes M1a, M1b stages or recurrent disease) (according to the 7th edition of the TNM classification system); however, patients with T4NX disease (stage III B) with nodule(s) in ipsilateral lung lobe are not eligible, because such patients were not included in historical controlsXx_NEWLINE_xXHistologically confirmed surgically incurable and unresectable Stage IIIC or Stage IV (AJCC) melanomaXx_NEWLINE_xXPatients must have histological or cytological confirmed melanoma that is metastatic or unresectable stage IIIc and clearly progressive.Xx_NEWLINE_xXPatients with confirmed unresectable Stage IIB or Stage III non-small cell lung cancer of any histologic-subtype appropriate for definitive concurrent chemotherapy and radiation as determined by multi-disciplinary assessment; all detectable tumor should be encompassable by radiation therapy fields, including both the primary tumor and the involved regional lymph nodesXx_NEWLINE_xXMixed histology or undifferentiated small cell carcinoma, any stageXx_NEWLINE_xXPatients with histologically documented diagnosis of advanced stage IV or unresectable stage III melanoma are eligibleXx_NEWLINE_xXLocally advanced head and neck (HN) squamous cell carcinoma (SCC), stages III, IV, and bulky (> 27 cm^3 volume) stage II, excluding larynx and nasopharynx, of no more than 150 cm^3 volume base on CT scanXx_NEWLINE_xXStage IB-IIIAXx_NEWLINE_xXPatients must have a histologically confirmed diagnosis (by either primary surgical specimen or biopsy for recurrence) of advanced stage (stage III or IV) or recurrent endometrioid endometrial cancerXx_NEWLINE_xXStage IV disease at the start of first-line chemotherapyXx_NEWLINE_xXHas received prior treatment with chemotherapy or biologic therapy for stage IV NSCLC.Xx_NEWLINE_xXNewly diagnosed untreated stage IV and/or recurrent after adjuvant therapy with metastatic diseaseXx_NEWLINE_xXPatients with histologically proven melanoma with metastasis that is unresectable Stage III or Stage IV. This will include bulky stage III and M1-3. Patients with melanoma with documented metastases to the brain are eligible.Xx_NEWLINE_xXStage III or IV disease at any time in the past (Ann Arbor Staging System for Non-Hodgkin’s Lymphomas)Xx_NEWLINE_xXPatients with stage IV disease with no more than five metastases in no more than two visceral organ sites will be eligible; if a multidisciplinary tumor board determines trial entry for an individual patient with stage IV exceeding this number of metastases is appropriate, that patient can be enrolledXx_NEWLINE_xXHistologically documented, Stage Ia to operable Stage IIIa, triple-negative carcinoma of the breast with primary tumor greter than or equal to (>/=) 1.5 centimeters (cm) in largest diameter (cT1-3) by MRIXx_NEWLINE_xXMetastatic (Stage IV) breast cancerXx_NEWLINE_xXMalignancies other than non-squamous NSCLC successfully treated within 3 years prior to randomization (with the exception of certain early-stage cancers)Xx_NEWLINE_xXResected, histologically proven, cutaneous melanoma determined to be Stage IIb, IIc, or III; according to the American Joint Commission of Cancer Staging, 7th editionXx_NEWLINE_xXNo prior treatment for Stage IV squamous NSCLCXx_NEWLINE_xXHistologically confirmed invasive breast carcinoma, with all of the following characteristics: (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm) in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer; (iii) Documented absence of distant metastases (M0)Xx_NEWLINE_xXAnn Arbor Stage II, III, or IVXx_NEWLINE_xXStage II, III or IV diseaseXx_NEWLINE_xXPreviously treated or untreated, unresectable Stage III or Stage IV malignant melanomaXx_NEWLINE_xXPatient must have an advanced stage malignancy defined as meeting at least one of the following criteria:Xx_NEWLINE_xXHistologically or cytologically confirmed Stage IIIB or Stage IV non-squamous non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXPrior systemic treatment for Stage IIIB or IV non-squamous NSCLCXx_NEWLINE_xXAll patients must be either Stage IIIb/c or Stage IV according to the American Joint Committee on Cancer (AJCC) (7th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable in order to be eligible. Please refer to the AJCC Cancer Staging Manual, 7th edition for a description of tumor, lymph node, metastasis and staging.Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic melanoma; this includes American Joint Committee on Cancer (AJCC) stage IV or advanced/inoperable stage III; this also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastasesXx_NEWLINE_xXSubjects with a confirmed or suspected diagnosis of stage IA to stage IIIA non-small cell lung cancer scheduled for a lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)5;Xx_NEWLINE_xXCervical carcinoma of Stage 1B or less.Xx_NEWLINE_xXHistologically or cytologically documented, locally advanced or metastatic (i.e., stage IIIB not eligible for definitive chemoradiotherapy, stage IV, or recurrent) NSCLC (per the American Joint Committee [AJCC] staging system)Xx_NEWLINE_xXWomen with unilateral stage I or II BCRLXx_NEWLINE_xXStage III lymphedemaXx_NEWLINE_xXRelapsed or refractory disease (Stage III or IV): NSCLC or pancreatic cancer must have failed at least 1 prior treatment. Breast cancer must have failed at least 2 prior treatments.Xx_NEWLINE_xXStage II disease with bulky disease (? 7cm lesion), Stage III, or Stage IV diseaseXx_NEWLINE_xXStage IV or Recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer (IASLC) classification)Xx_NEWLINE_xXPatients with stage IA to IIB disease; select patients with resectable stage IIIA disease (T3N1, T4N0, T4N1) will also be eligible if approved by the principal investigator (PI)Xx_NEWLINE_xXThis trial will include subjects with stage IB-IVB MF/SS (maximal stage since diagnosis will determine eligibility), and who have relapsed, are refractory, or progressed after at least one standard systemic therapy; current disease stage at time of entry will also be documented but will not be used for eligibilityXx_NEWLINE_xXSubjects will be staged according to the 2010 American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-4, N0 being eligible; and have a primary tumor of the pancreas (either pancreatic head, neck, uncinate process, or body/tail)Xx_NEWLINE_xXPathologically confirmed of advanced and/or metastatic stage IIIb/IV non-small cell carcinoma of lungXx_NEWLINE_xXHistologically or cytologically confirmed squamous cell carcinoma, previously untreated stage II, III, or IVA HNC; patients with clinical stage III or IVA disease must undergo computed tomography (CT) or magnetic resonance imaging (MRI) to rule out the presence of distant metastasesXx_NEWLINE_xX6 weeks from surgery for stage 1 or 2 Non Small Cell Lung CancerXx_NEWLINE_xXHistologically or cytologically documented advanced NSCLC who have Stage IIIB/Stage IV disease, or recurrent disease following radiation therapy or surgical resection or advanced, unresectable (Stage III) or metastatic (Stage IV) melanoma;Xx_NEWLINE_xXHistologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic) and determined to be BRAF V600E or V600K mutation-positive (cohort A) or mutation-negative (cohorts B and C)Xx_NEWLINE_xXStage 4c metastases.Xx_NEWLINE_xXHistologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)Xx_NEWLINE_xXDiagnosis of stage IV non-small cell lung cancer, or stages II-III NSCLC that cannot be treated curatively with standard techniquesXx_NEWLINE_xXResectable disease-clinical stage I (T/0/N0miT1N0-N0mi), IIA-IIIA (T2 N0/T3N0 or T1-3 N1-N2a) or unresectable disease – clinical stage IIIB/IIIC (T4 or T1-3 N2b-3); no evidence of metastatic diseaseXx_NEWLINE_xXHistologically documented recurrent or advanced (Stage IV) NSCLCXx_NEWLINE_xXPatients must have histologically confirmed recurrent stage III or stage IV melanoma (AJCC 7th edition classification); cutaneous melanoma, ocular or mucosal melanoma will be eligibleXx_NEWLINE_xXHistologically confirmed stage IV or unresectable stage III melanoma with documented BRAF V600 mutationXx_NEWLINE_xXHistologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXNo prior treatment for unresectable Stage IIIB or IV NSCLCXx_NEWLINE_xXHistologically or cytologically confirmed diagnosis: Arm A and B- stage IV recurrent metastatic squamous NSCLC with Fibroblast growth factor receptor 1 (FGFR1) gene amplification by central laboratory testing. Arm C- recurrent after local therapy or unresectable MPM with measurable lesions. For specific arms the following requirements: Arm A: Subjects who have received no prior therapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note, to avoid any undue delay of initiating systemic chemotherapy for these subjects with newly diagnosed metastatic disease, it is allowed to initiate the first cycle of chemotherapy while eligibility for the study is still being determined, as long as the first dose of GSK3052230 is given no later than Cycle 2 Day 1 of chemotherapy. In addition, subjects with Stage IIIB or Stage IV disease and recurrence after previous NSCLC that has been treated with surgery and adjuvant chemotherapy or a radio- chemotherapy regimen with curative intent are eligible, provided 6 months has passed since this treatment ended. Arm B: Subjects who have documented tumor progression (based on radiological imaging) or intolerability after receiving at least one prior line of platinum containing combination chemotherapy for Stage IIIB or Stage IV or recurrent metastatic disease. Note: Prior treatment should not include docetaxel but may have included paclitaxel. Arm C: Subjects who have received no prior systemic therapy for MPM.Xx_NEWLINE_xXLocally advanced or metastatic non-small cell lung cancer (stage IIIB or IV by AJCC 7th)Xx_NEWLINE_xXAmyloid cardiac biomarker stage I or II disease Staging defined by NT-proBNP and troponin T cut-offs of < 332 pg/mL and <0.035 ng/mL, respectively, as thresholds: Stage I, both under threshold; and Stage II, either troponin or NT-proBNP (but not both) over threshold. If troponin T is not available at local institution, troponin I may be used, but threshold is <0.1 ng/mL.23Xx_NEWLINE_xXHistologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic), and determined to be BRAF V600E or V600K mutation-positive by the local laboratory. Subjects with ocular or mucosal melanoma are not eligibleXx_NEWLINE_xXAdvanced (FIGO stage III or IV), recurrent or metastatic disease.Xx_NEWLINE_xXSecond line or greater/Refractory/Relapsed, Stage I, Stage II, Stage IIIXx_NEWLINE_xXAny stage disease is allowedXx_NEWLINE_xXPresumed early stage ovarian cancerXx_NEWLINE_xXRecurrent, satellite or in-transit locally advanced cutaneous or subcutaneous melanoma metastases (i.e., AJCC Stage IIIB, IIIC or Stage IV M1a with no active nodal metastases)Xx_NEWLINE_xXStage must be classified as one of the following:\r\n* Ann Arbor stage IA or IIA with:\r\n** Non-bulky mediastinal disease (< 33% mediastinal to thoracic ratio on chest x-ray [CXR])\r\n** < 3 nodal regions involved on the same side of the diaphragm\r\n** No “E” lesionXx_NEWLINE_xXIntermediate or high risk disease, defined as stage IB, IIIA, any IV or IA/IIA with “E” lesion(s), 3 or more nodal sites involved, or bulky mediastinal adenopathyXx_NEWLINE_xXHistological or cytological proven advanced (unresectable) or metastatic NSCLC as defined as stage IIIB (positive supraclavicular lymph nodes) not amenable to definitive chemoradiotherapy or stage IV NSCLCXx_NEWLINE_xXInclusion Criteria for Both Stages:\n\n          -  Measureable disease per RECIST v1.1 with tumor accessible for biopsy\n\n          -  Adequate hematologic and end organ function\n\n        Inclusion Criteria for Stage 1:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Metastatic or inoperable, locally advanced, histologically or cytologically confirmed\n             invasive HR-positive HER2-negative breast cancer\n\n          -  Recommended for endocrine therapy, and cytotoxic chemotherapy not indicated at study\n             entry\n\n          -  Recurrence or progression following most recent systemic breast cancer therapy\n\n          -  Disease progression during or after CDK4/6 inhibitor treatment for metastatic disease\n\n          -  Postmenopausal according to protocol-defined criteria\n\n          -  Life expectancy >3 years\n\n          -  Available tumor specimen for determination of PD-L1 status\n\n        Inclusion Criteria for Stage 2:\n\n          -  ECOG performance status of 0-2\n\n          -  Ability to initiate treatment within 3 months after disease progression or\n             unacceptable toxicity on a Stage 1 regimen\n\n        Exclusion Criteria for Both Stages:\n\n          -  Significant or uncontrolled comorbid disease as specified in the protocol\n\n          -  Uncontrolled tumor-related pain\n\n          -  Autoimmune disease except for stable/controlled hypothyroidism, Type 1 diabetes\n             mellitus, or certain dermatologic conditions\n\n          -  Positive human immunodeficiency virus or hepatitis B or C\n\n          -  Severe infection within 4 weeks and/or antibiotics within 2 weeks prior to study\n             treatment\n\n          -  Prior allogeneic stem cell or solid organ transplantation\n\n          -  History of malignancy other than breast cancer within 2 years prior to screening\n             except those with negligible risk of metastasis/death\n\n          -  History of or known hypersensitivity to study drug or excipients\n\n        Exclusion Criteria for Stage 1:\n\n          -  HER2-positive breast cancer\n\n          -  Prior fulvestrant or cytotoxic chemotherapy for metastatic breast cancer, or certain\n             other agents as specified in the protocol\n\n          -  Unresolved AEs from prior anti-cancer therapy\n\n        Exclusion Criteria for Stage 2:\n\n          -  Unacceptable toxicity with atezolizumab during Stage 1\n\n          -  Uncontrolled cardiovascular disease or coagulation disorder, including use of\n             anticoagulants as specified in the protocol\n\n          -  Significant abdominal or intestinal manifestations within 6 months prior to treatment\n\n          -  ProteinuriaXx_NEWLINE_xXUnresectable Stage III or Stage IV melanomaXx_NEWLINE_xXHistologically documented advanced (Stage IV) or recurrent squamous (Arms A and B) or non-squamous (Arms C, D, E, and F) non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXExtensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)Xx_NEWLINE_xXEnd-stage renal disease: requiring hemodialysisXx_NEWLINE_xXStage II, III or IV (Ann Arbor Staging)Xx_NEWLINE_xXHistologic diagnosis of melanoma with in transit metastasis stage IIIB, IIIC, or IVXx_NEWLINE_xXPart A2: Histologic or cytologic diagnosis of advanced Non Small Cell Lung Cancer (NSCLC), Stage IIIB with malignant pleural effusion or Stage IV, completed at least 1 prior systemic regimen, and eligible for erlotinib therapy.Xx_NEWLINE_xXNSCLC: --Histologic or cytologic diagnosis of advanced NSCLC, Stage IIIB with malignant pleural effusion or Stage IVXx_NEWLINE_xXParticipants must have clinical diagnosis of lung or bladder cancer; if the diagnosis of non-small cell lung cancer (NSCLC) or bladder cancer is confirmed, platinum-based chemotherapy must be planned either for neoadjuvant chemotherapy for stage II or above bladder cancer, or palliative therapy for stage III or IV bladder cancer or stage IV lung cancer regardless of patient participation in this study; stage II or above transitional cell carcinoma (TCC) patients and stage IV NSCLC patients that will receive platinum-based chemotherapy will be eligible for this study; patients with stage III or IV bladder cancer or stage IV lung cancer must have measurable lesion(s)Xx_NEWLINE_xXPatients must have histologically or cytologically confirmed metastatic melanoma (includes American Joint Committee on Cancer [AJCC] stage IV or advanced/inoperable stage III; also includes patients with a history of lower stage melanoma and subsequent recurrent metastatic disease that is either locally/regionally advanced/inoperable disease or distant metastases)Xx_NEWLINE_xXBarcelona Clinic Liver Cancer (BCLC) advanced stage (C) hepatocellular carcinoma, or BCLC intermediate stage (B) hepatocellular carcinoma if treatment with transarterial chemoembolization is not considered appropriateXx_NEWLINE_xXThe patient has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV diseaseXx_NEWLINE_xXThe participant has Stage IV disease at the time of study entry.Xx_NEWLINE_xXThe participant is currently or has previously received chemotherapy for advanced (Stage IV) NSCLC.Xx_NEWLINE_xXEarly stage breast cancer (stage I [tumor size >= 1 cm], II and IIIA)Xx_NEWLINE_xXHistologically proven recurrent urothelial carcinoma of the bladder or prostatic urethra, Stage Tis, TaXx_NEWLINE_xXStage IV disease at the time of study entryXx_NEWLINE_xXMust have histologically confirmed cutaneous metastatic melanoma (Stage IV) that is BRAF mutation-positive (V600 E/K) as determined via central testing with a BRAF mutation assay.Xx_NEWLINE_xXPatients must have suspected International Federation of Gynecology and Obstetrics (FIGO) stage III or IV diseaseXx_NEWLINE_xXHistologically confirmed cutaneous melanoma with unresectable stage III disease, or stage IV disease by American Joint Committee on Cancer (AJCC) criteriaXx_NEWLINE_xXHistologically or cytologically proven adenocarcinoma of the breast stages II-III, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2009Xx_NEWLINE_xXSubject has end stage renal disease and requires chronic dialysisXx_NEWLINE_xXInitial presentation: stage IV or metastatic disease, enrolled prior to any cytoreductive therapyXx_NEWLINE_xXAnn Arbor stage I disease.Xx_NEWLINE_xXPrimary melanoma with the following Breslow thickness and stage:\r\n* =< 2 mm\r\n* Patients with recent (within 12 weeks) biopsy of primary melanoma that has not been widely resected will be eligible for study according to the above-specified criteria for tumor thickness and stage; if more than one biopsy was done for the primary melanoma, the window of 12 weeks will be counted from the date of the last surgeryXx_NEWLINE_xXUnresectable stage III or stage IV M1a/M1b/M1c melanoma including patients with uveal melanomaXx_NEWLINE_xXBarcelona Clinic Liver Cancer (BCLC) stage BXx_NEWLINE_xXMycosis fungoides patients that have stage T2-4 N0-1 M0B0 diseaseXx_NEWLINE_xXPatient who have AJCC 8th edition Prognostic Stage Group IIXx_NEWLINE_xXDose escalation: Patients with metastatic melanoma with measurable, stage III (in transit lesions) or stage IVA, IVB or IVC disease (at least 2 measurable lesions/tumors; patients will be required to have one more lesion resent than the number the current dose level requires since one lesion will be left untreatedXx_NEWLINE_xXExpansion cohorts: Patients with metastatic melanoma with measurable, stage III (in transit lesions) or stage IVA, IVB or IVC disease at least two measurable lesions/tumorsXx_NEWLINE_xXHistologic diagnosis of unresectable stage IIIC or stage IV melanoma that is BRAF V600 mutation positiveXx_NEWLINE_xXInoperable or metastatic extra cranial stage III or IV diseaseXx_NEWLINE_xXPatients with either unresectable Stage IIIc or Stage IV metastatic melanoma positive for the BRAFV600 mutation or other malignant tumor type that harbors a V600-activating mutation of BRAF, as determined by results of cobas® 4800 BRAF V600 mutation test or a DNA sequencing method, and who have no acceptable standard treatment optionsXx_NEWLINE_xXFinal American Joint Committee on Cancer (AJCC) stage IIa – IIIa (pathologic stage T0N1a-2a, T1N1a-2a, T2N1a-2a, T3N0-2a, all M0 status); pathological stage for all patients not receiving neoadjuvant chemotherapy; higher of the clinical or pathological T and N stage, if receiving neoadjuvant chemotherapy; patients with pathological N0 at the time of mastectomy are only eligible if biopsy-proven clinically N1 or N2 disease is documented prior to induction chemotherapyXx_NEWLINE_xXAdvanced (stage IIIB or IV) lung adenocarcinoma diagnosed by biopsy of the primary or metastatic site (American Joint Committee on Cancer 7.0)Xx_NEWLINE_xXStage IV cancerXx_NEWLINE_xXPast history of treated (newly diagnosed or recurrent) breast, colorectal, prostate, gynecologic (only uterine and cervical) cancers (stage I, II, or III) or any stage lymphoma (Hodgkin’s or non-Hodgkin’s)Xx_NEWLINE_xXPatients with stage IA1 disease who are LVSI negativeXx_NEWLINE_xXPatients with >= stage IB2 diseaseXx_NEWLINE_xXDiagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; patients with a diagnosis of stage III cancer or lymphoma are eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowedXx_NEWLINE_xXPatients must have histologically or cytologically confirmed stage I-III breast cancer (as defined by the revised, American Joint Committee on Cancer [AJCC] 7th edition criteria) and be at sufficient risk for tumor recurrence; staging studies to exclude metastatic disease are not required in asymptomatic patients; however, patients with findings considered suspicious for metastatic disease on any staging studies that are obtained need to be evaluated to exclude stage IV breast cancerXx_NEWLINE_xXPHASE I: Diagnosis of stage I to III breast cancerXx_NEWLINE_xXPHASE II: Diagnosis of stage I to III breast cancerXx_NEWLINE_xXDiagnosis of a solid tumor malignancy (any stage)Xx_NEWLINE_xXPATIENT INCLUSION: Clinical diagnosis stage 4 solid or hematologic malignancy or nonresectable stage 3 gastrointestinal (Gi) cancerXx_NEWLINE_xXPatient has stage 3B or 4 non-small cell lung cancer (NSLC) or extensive stage small cell lung cancer (SCLC) and is within one month of treatment initiationXx_NEWLINE_xXExperiencing their first, stage 0 – IIIA breast cancer diagnosis (either clinical or definitive early stage at enrollment)Xx_NEWLINE_xXSurvivors with a primary diagnosis of stage I-III breast, ovarian, uterine, or endometrial cancerXx_NEWLINE_xXStage 3B BCXx_NEWLINE_xXInflammatory or stage 4 BCXx_NEWLINE_xXCancer stage: T1 - 4N x M0Xx_NEWLINE_xXDiagnosed with in situ or metastatic breast, prostate or colorectal cancer (i.e. stage 0 or IV)Xx_NEWLINE_xXWomen diagnosed with early stage, resectable breast cancer (Stage 0, I, II, or III) prior to age 45, and are within 5 years of diagnosisXx_NEWLINE_xXA diagnosis of stage IV breast cancerXx_NEWLINE_xXStage I-IIIXx_NEWLINE_xXStage IV breast cancerXx_NEWLINE_xXPatients with end-stage disease, severe dementia and/or life expectancy of less than one yearXx_NEWLINE_xXNewly diagnosed and surgically treated females with stage I-III breast cancerXx_NEWLINE_xXThree populations of patients are eligible for enrollment:\r\n* Patients with early stage disease at diagnosis (stage I-II) who were treated with chemotherapy alone and relapsed with early stage disease (stage RI-II)\r\n* Patients with early stage disease at diagnosis (stage I-II) who were treated with chemotherapy alone and have early stage (stage RI-II) primary refractory disease (residual disease on a scan 1 month after the completion of initial therapy) without B-symptoms and with each area of disease less than 10 cm in size\r\n* Patients with early stage disease at diagnosis (stage I-II) who were treated with combined modality therapy (chemotherapy and radiation) who relapse with early stage disease (stage RIII) outside the prior radiation therapy fieldXx_NEWLINE_xXAnn Arbor stage III or IV disease at diagnosis or at relapse/refractory disease confirmationXx_NEWLINE_xXStage IB-IVB MF/SS, and who have relapsed, are refractory, or progressed after at least one standard systemic therapy; maximal stage since diagnosis will determine eligibility; current disease stage at time of entry will also be documented but will not be used for eligibilityXx_NEWLINE_xXCOHORT A OVERVIEW: patients age less than 60 with untreated stage III or IV classical Hodgkin lymphoma will be eligible for cohort A; in phase I, patients may enroll onto cohort A if they have a baseline IPS ? 3 OR if their PET scan after 2 cycles of ABVD is positive (Deauville 4 or 5); enrollment onto phase I has now ceased and enrollment will begin for phase II; in phase II, patients less than 60 years of age with stage III or IV HL are eligible; patients may enroll anytime within the first 2 cycles of ABVD or after PET-2Xx_NEWLINE_xXAnn Arbor stage III or IV disease (Cohort A only)Xx_NEWLINE_xXPatients must have pathologically confirmed stage IV or unresectable stage III melanoma; patients must not have disease that is suitable for local therapy, administered with curative intentXx_NEWLINE_xXHistologically confirmed diagnosis of early stage breast cancer (stage I-III)Xx_NEWLINE_xX1-3 years post-completion of chemotherapy or/and radiation therapy for stage I-III breast cancerXx_NEWLINE_xXWomen newly diagnosed (stage I-III) breast cancerXx_NEWLINE_xXNewly diagnosed with stage I-III breast cancerXx_NEWLINE_xXDiagnosed with stage III or IV colorectal cancerXx_NEWLINE_xXDiagnosed with stage I, II, or III (a/b) breast cancerXx_NEWLINE_xXStage IV and/or metastatic solid tumor cancer diagnosis, or stage III pancreatic or lung cancer diagnosisXx_NEWLINE_xXDiagnosed with stage I-III lung cancerXx_NEWLINE_xXAny disease stageXx_NEWLINE_xXStage II-III breast cancerXx_NEWLINE_xXBe diagnosed with breast cancer at stage 0, I, II, III or IVXx_NEWLINE_xXClinical stage I ECXx_NEWLINE_xXPhase I: Diagnosis of primary pathologic stage 0–III cutaneous malignant melanomaXx_NEWLINE_xXPhase II: Diagnosis of primary pathologic stage 0–III cutaneous malignant melanomaXx_NEWLINE_xXPatients with end-stage renal disease defined as creatinine clearance of < 15mL/min and/or diagnosed with stage 5 chronic kidney diseaseXx_NEWLINE_xXLocalized endometrial cancer (stage I and II); no evidence of stage III or IV diseaseXx_NEWLINE_xXDiagnosis of stage I to III breast cancerXx_NEWLINE_xXPatients with stage I-III breast cancerXx_NEWLINE_xXDiagnosed with stage 0, I, II, or IIIa breast cancer, confirmed by medical recordXx_NEWLINE_xXParticipants must self-identify as having a medical history of histologically confirmed stage 0, I, II, III breast cancer, or I with no evidence of metastatic diseaseXx_NEWLINE_xXStage 5 chronic kidney disease or need for hemodialysisXx_NEWLINE_xXHave a history of stage I, II, or III breast cancerXx_NEWLINE_xXMetastatic breast cancer (stage IV)Xx_NEWLINE_xXMallampati IVXx_NEWLINE_xXAs per medical record, early stage prostate cancer (pathologic stage 1-2 with Gleason score =< 8; or pathologic stage 3 with Gleason score =< 7)Xx_NEWLINE_xXMetastatic breast cancer (MBC) diagnosis – Stage IVXx_NEWLINE_xXDCG: Is an adult family member (at least 18 years old) of a patient with an advanced-stage cancerXx_NEWLINE_xXDiagnosed with stage 0-III hormone-receptor positive breast cancer (BCa)Xx_NEWLINE_xXMetastatic (stage IV) BCaXx_NEWLINE_xXPATIENTS ONLY: Diagnosed with stage IV non-small cell lung cancer (NSCLC)Xx_NEWLINE_xXStage 3 or 4 under the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (IUCC) staging system OR patients with stage 1 or 2 disease who will receive radiation equivalent to patients with stage 3 or 4 diseaseXx_NEWLINE_xXDiagnosed with early stage (I-III) breast cancer, without evidence of metastatic diseaseXx_NEWLINE_xXAdvanced stage (stage IV) or metastatic breast cancer diagnosis (screening for metastases with scans only needed if there is clinical suspicion for metastases)Xx_NEWLINE_xXPatients with stage II – IV non squamous cell NSCLC who received at least 54 Gy of total planned thoracic radiation dose will be eligible; patients must have received at least one cycle of chemotherapy concurrently during the course of thoracic radiation; regimens allowed are platinum combinations with either etoposide or a taxane regardless of histology subtype; platinum with pemetrexed for patients with non-squamous NSCLC only; patients with oligometastatic stage IV cancer are eligible if they have received only one line of systemic therapy for their stage IV cancer prior to the concurrent chemoradiation phaseXx_NEWLINE_xXPhase 1: Early stage (stage 1 and 2) CRC survivors who are 6 month or greater post-treatmentXx_NEWLINE_xXPrior diagnosis of stage 0 to stage III breast cancerXx_NEWLINE_xXWomen who have been diagnosed with stage I-IIIA breast cancer will be recruited 1-8 years after the completion of all primary cancer treatment except for longer-term hormonal therapies (tamoxifen, aromatase inhibitors); recruit women who have received one of the two most common stage I-IIIA chemotherapy regimens, either docetaxel/cyclophosphamide or doxorubicin/cyclophosphamide followed by paclitaxel to provide uniformity of prior treatmentXx_NEWLINE_xXTumor stage II or greaterXx_NEWLINE_xXHave a diagnosis of breast cancer (BC) (stage I-III)Xx_NEWLINE_xXIdentified as the active or maintenance stage of exercise behaviorXx_NEWLINE_xXWomen with stage II or III breast cancer that will be scheduled to undergo a 4 to 6-week course of radiotherapyXx_NEWLINE_xXConfirmed diagnosis of metastatic or stage IV BCXx_NEWLINE_xXDiagnosed with stage I-III colorectal cancerXx_NEWLINE_xXBreast cancer stage I-IIIXx_NEWLINE_xXStage I-III colorectal cancer (CRC).Xx_NEWLINE_xXHistologic or cytologic proven breast cancer or colon cancer (stage I, II or III)Xx_NEWLINE_xXPATIENTS: Newly diagnosed with any stage cancerXx_NEWLINE_xXEligible disease(s)/stage(s): nasopharyngeal carcinoma, paranasal sinus cancers/any stageXx_NEWLINE_xXHas a new or recurrent American Joint Committee on Cancer (AJCC) stage I-IV squamous cell carcinoma of the upper aerodigestive tract (including lip/oral cavity, nasopharynx, salivary gland, oropharynx, hypopharynx, paranasal sinus, and larynx cancers)Xx_NEWLINE_xXSTAGE IXx_NEWLINE_xXSTAGE IIXx_NEWLINE_xXDiagnosis of adenocarcinoma colorectal cancer (stage I, II, III, IV)Xx_NEWLINE_xXPHASE I AIM 1: Malignant diagnosis in any cancer type at any stageXx_NEWLINE_xXPHASE I AIM 3.1: Malignant diagnosis in any cancer type at any stageXx_NEWLINE_xXPHASE II AIM 2: Malignant diagnosis of breast, lung, or colorectal cancer at any stageXx_NEWLINE_xXPatients with early-stage breast cancer (stage I-III)Xx_NEWLINE_xXPatients with stage IV breast cancerXx_NEWLINE_xXPatients with advanced or stage IIIC or IV breast cancer or other cancersXx_NEWLINE_xXDiagnosis of stage I-III cancers of the rectosigmoid colon or rectumXx_NEWLINE_xXPatients with stage IV disease will be excluded from the studyXx_NEWLINE_xXHave a clinical stage II-IV head and neck carcinomaXx_NEWLINE_xXPatients with American Joint Committee on Cancer (AJCC) stage II-IV head and neck squamous cell carcinoma who are beginning first-line non-surgical treatment with concurrent chemoradiotherapy (CCRT) and who are capable of understanding and adhering to the protocol requirementsXx_NEWLINE_xXPatients must have stage III or IV cancer diagnosisXx_NEWLINE_xXNewly diagnosed with high grade stage 2, any grade stage 3 or higher endometrial cancer in the past 6 monthsXx_NEWLINE_xXNewly diagnosed with stage 2 or higher cervical cancer within the past 6 monthsXx_NEWLINE_xXNewly diagnosed with any stage of uterine cancer (both sarcoma and carcinosarcoma) in the past 6 monthsXx_NEWLINE_xXPrimary family caregivers of cancer patients who are diagnosed with stage II-IV diseaseXx_NEWLINE_xXStage II or III unilateral secondary upper extremity lymphedema (as defined by the International Society of Lymphology)Xx_NEWLINE_xXDiagnosis of an advanced solid tumor malignancy (advanced cancer) or lymphoma; in most situations, this would be a stage IV cancer; a patient with a diagnosis of stage III cancer or lymphoma is eligible if cure is not possible or anticipated; clinical staging without pathological confirmation of advanced disease is allowedXx_NEWLINE_xXMetastatic disease (Stage IV C)Xx_NEWLINE_xXWomen diagnosed with stage I-IV ovarian cancerXx_NEWLINE_xXCaregivers of patients who have been diagnosed with stage IV gastrointestinal (GI) cancerXx_NEWLINE_xXPatient participants must have stage III, IV and/or recurrent NSCLCXx_NEWLINE_xXEnd stage renal disease (ESRD)Xx_NEWLINE_xXDiagnosed with stage 0-III breast cancer within the past 3 yearsXx_NEWLINE_xXA diagnosis of breast cancer, stage I, II, or IIIXx_NEWLINE_xXWomen with stage 0-III breast cancer who will be undergoing daily adjuvant radiation for 4-6 weeks (patients only)Xx_NEWLINE_xXHistory of histologically or cytologically proven stage I-III breast cancer receiving intravenous chemotherapy on an every 14 days or every 21 days scheduleXx_NEWLINE_xXHistory of stage 0-III breast cancerXx_NEWLINE_xXDiagnosed with stage I-II endometrial cancerXx_NEWLINE_xXStage IV or stage IIIB cancerXx_NEWLINE_xXHas diagnosis of non-recurrent stage I-III breast cancerXx_NEWLINE_xXHistory of endometrial cancer stage I-IV > 6 months < 5 years, not currently receiving cancer treatmentXx_NEWLINE_xXStage I-IIIXx_NEWLINE_xXStage IV breast cancerXx_NEWLINE_xXPatients with end-stage disease, severe dementia and/or life expectancy of less than one yearXx_NEWLINE_xXHave been diagnosed within one month with a pathologically confirmed advanced cancer who have an average of < 2 year (y) life expectancy (primary stage IV hepatobiliary, esophageal, colorectal, glioblastoma, gastric, pancreatic, melanoma, head and neck, or stage III or IV lung or pancreatic cancers) and are being treated at one of the participating hospital sites and speak English or SpanishXx_NEWLINE_xXPATIENT: Be diagnosed with an incurable and advanced-stage solid malignancy (stage IIIB, IIIC, or IV)Xx_NEWLINE_xXSCREENING PHASE: Histologically proven stage I-III carcinoma of the breastXx_NEWLINE_xXSCREENING PHASE: Known metastatic (stage IV) breast cancer involvementXx_NEWLINE_xXINTERVENTION PHASE: Histologically proven stage I-III carcinoma of the breastXx_NEWLINE_xXINTERVENTION PHASE: Known metastatic (stage IV) breast cancer involvementXx_NEWLINE_xXHistory of stage 0-III breast cancer or stage I-III ovarian cancer; all antitumor therapies, excluding hormonal therapy, have been completed at least 60 days prior to enrollmentXx_NEWLINE_xXNo evidence of distant metastasis representing stage IV metastatic diseaseXx_NEWLINE_xXHave end stage renal diseaseXx_NEWLINE_xXBarcelona Clinic Liver Cancer (BCLC) Stage C disease or BCLC Stage B disease not amenable to locoregional therapy or refractory to locoregional therapy.Xx_NEWLINE_xXHistological or cytological confirmation of Stage IIIb or Stage IV (unresectable) NSCLCXx_NEWLINE_xXSubjects with newly diagnosed stage I (T > 1 cm), II or III TNBC who have not undergone definitive breast surgery and have not received systemic chemotherapy will be eligibleXx_NEWLINE_xXHistory of histologically or cytologically proven breast cancer at stage I, II and III, without evidence of distant metastasisXx_NEWLINE_xXHistory of histologically or cytologically proven breast cancer at stage I, II and III without evidence of distant metastasisXx_NEWLINE_xXStage II only: have access to the Internet or a smart phoneXx_NEWLINE_xXDiagnosed with stage IV diseaseXx_NEWLINE_xXStage III/IV cancerXx_NEWLINE_xXDiagnosis of stage III-IV epithelial ovarian cancer (EOC)Xx_NEWLINE_xXSubjects with stage IV NSCLC (not recurrent or re-staged).Xx_NEWLINE_xXHistologic or cytologic confirmation of head & neck cancer (stage I-IV) or non-small cell lung cancer (stage II & III)Xx_NEWLINE_xXStage I, II, and III prostate cancerXx_NEWLINE_xXT stage greater than clinical T1Xx_NEWLINE_xXDiagnosis of stage 0 to III breast cancerXx_NEWLINE_xXPatients with T1 or T2 disease with N2 or T3N1-2 disease (stage IIIA) are eligible if they are medically inoperable; patients with T4 with any N or any T with N3 disease are eligible; radiographic evidence of mediastinal lymph nodes > 2.0 cm in the largest diameter is sufficient to stage N2 or N3 disease; if the largest mediastinal node is < 2.0 cm in diameter and this is the basis for stage III disease, then at least one of the nodes must be proven positive cytologically or histologicallyXx_NEWLINE_xXNewly diagnosed breast cancer (stage I, II, III)Xx_NEWLINE_xXHave diagnosis of breast cancer stage IVXx_NEWLINE_xXStage I-IV gynecologic cancer (including ovarian, uterine, cervical, vulvar, or vaginal cancer)Xx_NEWLINE_xXHas metastatic disease (M1) Stage IV CXx_NEWLINE_xXSpouses of women with diagnosed within the past 8 months with stage III or IV ovarian cancer will be eligible to participate, as will the diagnosed wife/partnerXx_NEWLINE_xXWomen diagnosed with stage IV ovarian cancer and who are hospice eligibleXx_NEWLINE_xXDiagnosis of stage III or stage IV cancerXx_NEWLINE_xXCaregivers will be eligible for enrollment if they identify as the person who is the caregiver of a patient diagnosed with advanced cancer (stage IV, solid tumor)Xx_NEWLINE_xXHave been diagnosed with stage I-III colon or rectal adenocarcinomaXx_NEWLINE_xXBreast cancer (stage 0, I, II, III), 18 months to 5 years post oncologic therapies of surgery, chemotherapy, and/or radiation therapy (does not exclude current selective estrogen receptor modulators or aromatase inhibitors)Xx_NEWLINE_xXNewly diagnosed with stage I-III breast cancerXx_NEWLINE_xXPatients diagnosed with GOLD Stage IV Emphysema.Xx_NEWLINE_xXSTAGE 1:Xx_NEWLINE_xXSTAGE 2 PATIENT PARTICIPANTS:Xx_NEWLINE_xXDiagnosis of stage I, II, or III ovarian cancerXx_NEWLINE_xXPatients with stage 0-III breast cancer, status-post surgery treated with standard chemotherapy/chemoprevention and/or radiationXx_NEWLINE_xXMetastatic disease (Stage IV C)Xx_NEWLINE_xXHistory of stage I-III breast, gastrointestinal or gynecologic cancerXx_NEWLINE_xXDiagnosed with stage I-III cancer other than cancers of the brain or spinal cord (confirmed by patient self-report on the Health History Questionnaire; if patient is unable to confirm either the site of her cancer or that her stage of cancer is < stage IV, we will send a letter to her physician to confirm this criterion)Xx_NEWLINE_xXCurrently stage IV (metastatic) breast cancer on the basis of definitive imaging or biopsy with\r\nstable disease (scans within the past 2 months)Xx_NEWLINE_xXT stage >= T3 (mass extending outside the bladder)Xx_NEWLINE_xXPatients with end stage renal disease (ESRD) and/or on dialysisXx_NEWLINE_xXT stage: cTis – T2Xx_NEWLINE_xXFor pre-surgical patients\r\n* Suspected diagnosis of resectable non-small cell lung cancer; cancers with a histology of “adenosquamous” are considered a type of adenocarcinoma and thus a “nonsquamous” histology; patients with squamous cell carcinoma are eligible only if the registering site has\r\nEA5142 Institutional Review Board (IRB) approved\r\n* Suspected clinical stage of IIIA, II (IIA or IIB) or large IB (defined as size >= 4cm); Note: IB tumors < 4cm are NOT eligible; stage IB cancer based on pleural invasion is not eligible unless the tumor size is >= 4cmXx_NEWLINE_xXFor post-surgical patients\r\n* Completely resected non-small cell lung cancer with negative margins (R0); patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved\r\n* Pathologic stage IIIA, II (IIA or IIB) or large IB (defined as size >= 4 cm); Note: IB tumors < 4cm are NOT eligible; stage IB cancer based on pleural invasion is not eligible unless the tumor size is >= 4cmXx_NEWLINE_xXPrevious diagnosis of stage 4 cancerXx_NEWLINE_xXScheduled for surgery at Brigham and Women’s Hospital for known or highly suspected stage III or IV ovarian cancer (i.e. elevated cancer antigen [CA]-125 with a pelvic mass, ascites, and carcinomatosis)Xx_NEWLINE_xXNo measurable disease or suspected stage I or II ovarian cancer on preoperative imagingXx_NEWLINE_xXHave end-stage renal diseaseXx_NEWLINE_xXEnd Stage Renal Disease (ESRD)Xx_NEWLINE_xXParticipants must have histologically confirmed malignancy that is metastatic or currently unresectable; eligible malignancies include:\r\n* Adenocarcinoma of the pancreas (locally advanced or metastatic)\r\n* Colorectal (stage IV)\r\n* Non-small cell lung cancer (currently unresectable stage III or stage IV)Xx_NEWLINE_xXAJCC stage I - III non-inflammatory, HER2-positive (according to ASCO-CAP guidelines 5) breast cancerXx_NEWLINE_xXAJCC Stage IV breast cancerXx_NEWLINE_xXDocumentation of WHO clinical stage 3 or 4 condition within 6 months of entryXx_NEWLINE_xXPatients must have completed curative-intent therapy (including surgery, radiation, and/or chemotherapy) for a first tobacco-related oral premalignant lesion (OPL) or HNSCC of any stage (eligible lesions include high grade dysplasia; carcinoma in situ; or stage I-IVa HNSCC); NOTE: the presence of a measurable OPL at baseline is not requiredXx_NEWLINE_xXKnown diagnosis of stage III colon or rectal cancer will be excluded from the studyXx_NEWLINE_xXStage II, III, or IV NSCLC for whom radiation therapy of 60 Gy and concurrent weekly paclitaxel/carboplatin is recommendedXx_NEWLINE_xXEnd stage renal disease with hemodialysisXx_NEWLINE_xXClinical stage T2c or lessXx_NEWLINE_xXPathologic stage T0-T3N0-N1M0Xx_NEWLINE_xXHistory of previous malignancies unless the cancer was stage I or II and rendered free of disease more than 1 yearXx_NEWLINE_xXStage I-III breast cancer (including inflammatory and newly diagnosed recurrent breast cancer) or lymphoma stage I-IV; (patients should have a > 2 year life expectancy)Xx_NEWLINE_xXHistologically confirmed stage IV gastrointestinal (GI) cancer (American Joint Committee on Cancer [AJCC] 7th edition) currently sensitive to oxaliplatin containing chemotherapy regimenXx_NEWLINE_xXStage IV or distant metastatic diseaseXx_NEWLINE_xXThe patient has diagnosis of stage IV disease or is found to have stage IV disease prior to randomizationXx_NEWLINE_xXParticipants undergoing definitive surgery at diagnosis must have pathologic stage II or III diseaseXx_NEWLINE_xXParticipants undergoing preoperative systemic therapy must have clinical stage II or III disease at presentation (clinical stage I disease is excluded)Xx_NEWLINE_xXPatients with NSCLC (adenocarcinoma, squamous, or adenosquamous histopathology) must also meet the following criteria: a. Must have disease that is stage IIIB, not curable by surgery or radiotherapy, or stage IV; b. Must have received at least one prior chemotherapy regimen for locally advanced or metastatic disease; c. EGFR-positive or ALK-positive patients must have received at least one line of EGFR-directed or ALK-directed therapy, respectively; d. Must have received prior taxane therapy.Xx_NEWLINE_xXHistory of stage I-III breast cancerXx_NEWLINE_xXSevere obstructive lung disease (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage III or IV, FEV1 < 30% predicted)Xx_NEWLINE_xXSubject has metastatic disease (M1) Stage IV-C.Xx_NEWLINE_xXHas end-stage renal impairmentXx_NEWLINE_xXEarly stage and/or treatment naïve, orXx_NEWLINE_xXPrimary tumor stage T1-3 at initial diagnosisXx_NEWLINE_xXStage II-IV epidermoid cancer of the head and neck OR stage III-IV pancreatic cancer, with prognosis of at least three months, per oncologistXx_NEWLINE_xXDiagnosed with stage I or II pancreatic cancer or with anticipated survival of less than three monthsXx_NEWLINE_xXPathologically confirmed diagnosis of breast cancer, clinical stage I-II (T1-3 N0 M0, T0-2 N1 M0); diagnosis must be by needle biopsy; patients diagnosed by surgical excision are excluded; for patients enrolled after receipt and completion of neoadjuvant chemotherapy, the clinical stage must be determined based on pre-chemotherapy assessmentXx_NEWLINE_xXThe study population will include women with stage IB1 cervical cancer (any histologic subtype) deemed eligible for surgery, and women with a clinical stage I high-grade endometrial cancer planning to undergo surgical staging; high grade is defined by the following:\r\n* Uterine serous carcinoma \r\n* Clear cell endometrial carcinoma  \r\n* Grade 3 endometrioid carcinoma \r\n* Endometrial carcinosarcomaXx_NEWLINE_xXFOR STAGE 2:Xx_NEWLINE_xXParticipants must have biopsy confirmed and clinical stage I, stage II, or stage III noninflammatory breast carcinoma; if biopsy was done at an outside hospital, pathology will be reviewed at (BWH, Brigham and Women's Faulkner Hospital [BWFH])Xx_NEWLINE_xXParticipants must have biopsy confirmed and clinical stage 1 or stage 2 breast carcinoma; if biopsy was done at an outside hospital, pathology will be reviewed at Brigham and Women's Hospital (BWH)/Dana-Farber Cancer Institute (DFCI)Xx_NEWLINE_xXPathologically or cytologically confirmed diagnosis of metastatic (stage IV) RAS wildtype CRCXx_NEWLINE_xXPatients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIICXx_NEWLINE_xXPatients receiving once daily fractionated intrathoracic radiation therapy for:\r\n* Stage IIA-IIIB non-small cell lung cancer\r\n* Limited stage small cell lung cancer\r\n* Stage I-III esophageal cancer (neoadjuvant or definitive)\r\n** For esophageal patients, accrual will be limited to patients that are NOT receiving trastuzumabXx_NEWLINE_xXHave histologic or cytologic biopsy-proven diagnosis of unresectable stage III or distant metastatic melanoma, irrespective of histologic type (i.e. cutaneous, unknown primary, mucosal, or ocular); patients with resectable bulky stage IIIB or stage IIIC melanoma (for example at least 2.5-cm in shortest diameter for lymph nodes infiltrated by tumor and at least 2-cm in longest diameter for non-lymph nodes infiltrated by tumor) can also be entered into the study at the discretion of the principal investigatorXx_NEWLINE_xXAny tumor stage, any N, M0Xx_NEWLINE_xX> stage 3 heart failureXx_NEWLINE_xXMelanoma tumor that meets indications for a groin SLN biopsy with a >= 10% risk of having metastasis to the draining lymph node (i.e. stage IB to stage IIIC melanoma of the lower body below the umbilicus)Xx_NEWLINE_xXClinical stage > T2b or evidence of nodalXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) stage I to IV lung cancer requiring radiation therapy (3-dimensional [3D] conformal or stereotactic) or systemic therapy, with or without surgeryXx_NEWLINE_xXAny stage is eligibleXx_NEWLINE_xXBiopsy proven, clinical stage 1-3 prostate carcinomasXx_NEWLINE_xXPatients without known bone metastases who are newly diagnosed with ? stage 3 breast cancer, ? stage 3 lung cancer, or ? stage 2 prostate cancer (and/or PSA >10 micrograms/L), including patient with recurrent breast, lung or prostate cancerXx_NEWLINE_xXSubjects with AJCC 7th edition stage TxN0 and M1 diseaseXx_NEWLINE_xXSubjects with AJCC 7th edition stage TxN0, T4b, and M1 diseaseXx_NEWLINE_xXClinical stage: =< T2a & N0 or NX & M0 or MXXx_NEWLINE_xXPrimary or locally recurrent stage I-IIA non-small cell lung cancer (NSCLC): T1-T2 N0 M0; tumor must be large enough to be above the detection threshold of PET imaging as determined by study investigatorsXx_NEWLINE_xXMelanoma tumor that requires a wide local excision in the operating room; this may include any stage of melanoma from stage IA to stage IV that requires a wide excision in the operating roomXx_NEWLINE_xXPatients must have pathologically documented advanced NSCLC (stage IV or recurrent)Xx_NEWLINE_xXPatient’s clinical stage must be documented as tumor size less than 5 cm, with no palpable nodes and no evidence of metastatic disease (T1 or T2 N0 M0); for patients who will receive neoadjuvant systemic therapy, pre-treatment clinical stage should be usedXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) stage I, II, III or IV non-small-cell lung cancer as well as distant metastasis within the lung to be treated using radiotherapy will be eligible for this studyXx_NEWLINE_xXStage IV breast cancerXx_NEWLINE_xXParticipants with known metastatic (stage IV) prostate cancerXx_NEWLINE_xXPatients must be deemed appropriate for doxorubicin-based chemotherapy regardless of individual diagnosis or stage of diseaseXx_NEWLINE_xXHistologically confirmed or suspected stage III or IV high-grade serous ovarian cancerXx_NEWLINE_xXStage I-IV disease\r\n* For patients with stage I-IIIC disease:\r\n** Scheduled for lumpectomy or mastectomy or considered a candidate for therapeutic systemic treatment\r\n** No prior or current therapy for breast cancer \r\n* For patients with stage IV disease: \r\n** Previously untreated for breast cancer with breast mass intactXx_NEWLINE_xXPatient has stage IIIB (and is not a candidate for definitive multimodality therapy) or has stage IV NSCLC or relapsed locally advanced or metastatic NSCLC as follows:Xx_NEWLINE_xXPatients must have stage I or II disease based on the parameters for staging NSCLC found in the American Joint Committee on Cancer (AJCC) cancer staging handbook, seventh (7th) editionXx_NEWLINE_xXPatients with a diagnosis of advanced stage disease (stage III or IV)Xx_NEWLINE_xXPatients with newly diagnosed and untreated stage II and II breast cancer scheduled to undergo neoadjuvant chemotherapyXx_NEWLINE_xXPatients must meet one (or more) of the following criteria:\r\n* Preoperative diagnosis of ovarian, fallopian tube, or primary peritoneal carcinoma (all stage, grade and histology)\r\n* Preoperative diagnosis of grade III endometrial carcinoma (all stage, all histology)\r\n* Preoperative diagnosis of uterine serous carcinoma (all stage, all grade)\r\n* Preoperative diagnosis of clear cell endometrial carcinoma (all stage, all grade)\r\n* Preoperative diagnosis of endometrial carcinosarcoma (all stage, all grade)\r\n* Gastrointestinal carcinoma (all histology, stage and grade)\r\n* Pancreatic carcinoma (all histology, stage and grade)\r\n* Lung cancer (all histology, stage and grade)\r\n* Esophageal carcinoma (all histology, stage and grade)\r\n* Suspected or pathologically confirmed metastatic disease to the lung (all disease primaries)\r\n* Suspected or pathologically confirmed malignant pleural effusion (all disease primaries)Xx_NEWLINE_xXPatients who have bladder tumors of stage >= T3; orXx_NEWLINE_xXSubjects must be diagnosed with histologically proven stage IV (metastatic) melanoma or stage III with bulky disease which may or may not be amenable for surgery and are receiving therapy at presentXx_NEWLINE_xXSubjects must be classified as TNM stage I, II, or III; alternatively, subjects may be classified as Barcelona Clinic Liver Cancer (BCLC) stage A or BXx_NEWLINE_xXPatient must have stage IIIA non-small cell lung cancer (T1-3N2) per American Joint Committee on Cancer (AJCC) 7th edition and must be considered to be surgically resectableXx_NEWLINE_xXEligible patients must have appropriate staging studies identifying them as specific subsets of American Joint Committee on Cancer (AJCC) 7th edition stage I or II based on only one of the following combinations of tumor, nodes, metastatic (TNM) staging:\r\n* T1a-b, N0, M0\r\n* T2a, N0, M0\r\n* T3 (invading the chest wall, < 5 cm in diameter) N0 M0Xx_NEWLINE_xXPathological T3 stage of disease (i.e., EPE or SVI), orXx_NEWLINE_xXPatients should have pathologically or cytologically confirmed stage IV non-small cell lung cancer with clinical or radiological evidence that it is not amenable to therapy with curative intent; prior EGFR tyrosine kinase inhibition (TKI) therapy is permitted but not requiredXx_NEWLINE_xXPatient must have clinical American Joint Committee on Cancer, 6th edition stage II or III breast cancer and be considered a candidate for curative mastectomyXx_NEWLINE_xXNo prior radiation therapy or systemic treatment is allowed for patients undergoing resection of stage I, II, or III colon cancerXx_NEWLINE_xXPrior systemic therapy, radiotherapy, or investigational agent in participants undergoing surgery for stage I, II, or III colon cancerXx_NEWLINE_xXSubjects with unresectable Stage III or IV melanoma who are either refractory or intolerant to, or have refused standard therapy for treatment of metastatic melanomaXx_NEWLINE_xXAll patients with early stage (stage I-III) non-small cell lung cancer, adenocarcinoma histologyXx_NEWLINE_xXA treatment plan involving levels I-III, I-IV, II-III, or II-IV, as recommended by National Comprehensive Cancer Network (NCCN) guidelinesXx_NEWLINE_xXFor stage IV disease:\r\n* Scheduled for surgical resection of oligometastatic disease\r\n* Previously untreated for breast cancerXx_NEWLINE_xXlocoregional OSCC (T stage II-IV) of the oral cavity, oropharynx, larynx, or hypopharynx without evidence of distant metastasesXx_NEWLINE_xXStage IV breast cancerXx_NEWLINE_xXOn average, cares for at least 3 AA patients with early stage NSCLC per year (based on the last 3 years of cancer registry data)Xx_NEWLINE_xXLocally advanced (stage IIIA-IIIB) or metastatic (stage IV) NSCLCXx_NEWLINE_xXDiagnosed with stage IV breast cancer within the past 3 yearsXx_NEWLINE_xXPathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group [ECOG] performance status, and any NSCLC – adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;\r\n* Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)Xx_NEWLINE_xXNewly diagnosed patients for the following conditions\r\n* Colon cancer stage III and IV\r\n* Rectal cancer stage II, III, IV\r\n* Glioblastoma multiforme (brain) -- no stage\r\n* Non-small cell lung cancer stage IIIA, IIIB, IV\r\n* Small cell lung cancer, limited stage and extensive stage\r\n* Castration-resistant prostate cancer\r\n* Head and neck cancer stage III and IV\r\n* Gastric cancer stage III and IV\r\n* Esophageal cancer stage III and IV\r\n* Pancreatic cancer stage II, III, IV\r\n* Renal cell carcinoma, stage IV\r\n* Breast cancer, stage IV, if triple negative ER/PR/H2N negative or on systemic chemotherapy\r\n* Sarcoma, stage IV\r\n* Bladder carcinoma, stage IV\r\n* Acute myeloid leukemia\r\n* Melanoma, stage III and IV\r\n* Ovarian cancer, stage III and IV\r\n* High grade myelodysplastic syndrome (MDS)Xx_NEWLINE_xXNewly diagnosed suspected or proven clinical stage I NSCLC (T1 or T2, N0, M0) with no prior treatment for this diseaseXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) stage 1, 2, 3 breast carcinomaXx_NEWLINE_xXFirst diagnosis with stage 1-2 breast or stage 1-2 lung cancer; and voluntary participationXx_NEWLINE_xXAND diagnosed with Stage I-III incident breast or colorectal cancers;Xx_NEWLINE_xXPatients with in situ cancers (Stage 0) and those with metastatic disease (Stage IV);Xx_NEWLINE_xXCancer Registry cases include stage I-III colon cancer (adenocarcinoma histology), stage I-III rectal cancer (adenocarcinoma histology), stage I-III non-small cell lung cancer (squamous or adenocarcinoma histology)Xx_NEWLINE_xXStage IV cancer or evidence of metastatic disease at any time pointXx_NEWLINE_xXStage 4 patients are not eligibleXx_NEWLINE_xXClinical stage < cT3Xx_NEWLINE_xXAdequately treated Stage I or II cancer from which the subject is currently in complete remissionXx_NEWLINE_xXHas histologically confirmed, unresectable Stage III or Stage IV melanoma per the American Joint Committee on Cancer (AJCC) staging system.Xx_NEWLINE_xXEnd-stage renal disease (ESRD) on hemodialysis or CrCl ? 75 mL/minXx_NEWLINE_xXLocally advanced or metastatic (stage IIIB, stage IV, or recurrent) NSCLC with measurable lesions per RECIST version 1.1.Xx_NEWLINE_xXHistologically confirmed recurrent or metastatic HNSCC (oral cavity, pharynx, or larynx) that is stage III/IV and not amenable to local therapy with curative intent (surgery or radiation therapy with or without chemotherapy).Xx_NEWLINE_xXClinical stage: T3/T4Xx_NEWLINE_xXHave a Stage IV diagnosis of 1 of the following: Part A: NSCLC (Kirsten rat sarcoma mutant [KRAS mt], PD-L1+); Part B: NSCLC (squamous histology); or Part C: metastatic breast cancer (HR+, HER2-).Xx_NEWLINE_xXParticipants must have progressive, advanced cancer as defined by one of the following:\r\n* Newly diagnosed, untreated advanced disease\r\n* Newly diagnosed, untreated metastatic recurrence of earlier stage disease (previous treatment of early stage disease allowed)\r\n* Clinical determination of progressive disease on previous systemic therapy as evidenced by plan to change treatment; any number of prior therapies are acceptable excluding previous EGFR kinase inhibitorsXx_NEWLINE_xXAmerican Joint Committee on Cancer (AJCC) 7th edition (ed.) stage cN0 or cN1 subsequently staged after surgery as stage pIB (N1mic), pIIA, pIIB, pIIIA, pIIIB, or N3a (10 or more axillary nodes) only: note that ypN0 will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node negative at the time of surgery; note that women less than 50 years of age, women who received chemotherapy, patients staged as pN0 (i+ or mol+), and large-breasted women are eligible for enrollmentXx_NEWLINE_xXHistologically or cytologically confirmed stage IV (metastatic) NSCLC as defined by American Joint Committee on Cancer (AJCC); recurrent but not metastatic disease is allowed if deemed incurableXx_NEWLINE_xXClinical stage T2-T4a, N0, M0 urothelial bladder cancerXx_NEWLINE_xX